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1 Summary 
 
Xanthohumol is the major prenylated chalcone found in hops, and it has been 
shown to exhibit various biological effects. However, xanthohumol effects on liver 
cells or in liver diseases, respectively, are widely unknown. 
In the present work, first the effects of xanthohumol on hepatic stellate cells 
(HSC), the central mediators of liver fibrogenesis, were analyzed. Xanthohumol 
inhibited the activation of primary human HSC and induces apoptosis in activated 
HSC in vitro in a dose dependent manner (0-20 µM). In contrast, xanthohumol 
doses as high as 100 µM did not impair viability of primary human hepatocytes 
(PHH). However, in both cell types xanthohumol inhibited NFκB activation and 
expression of NFκB dependent proinflammatory chemokines. In vivo, feeding of 
xanthohumol reduced levels of serum transaminases and hepatic expression of 
proinflammatory genes in a murine model of non-alcoholic steatohepatitis (NASH). 
Moreover, xanthohumol treatment significantly inhibited hepatic expression of 
profibrogenic genes and activation of HSC in vivo.  
Next, xanthohumol effects on hepatocellular carcinoma (HCC) cells were 
investigated. Xanthohumol concentration of 25 µM induced apoptosis in two HCC 
cell lines (HepG2 and Huh7). Furthermore, xanthohumol repressed proliferation 
and migration, as well as TNF induced activation of the transcription factor NFκB 
and interleukin-8 expression in both cell lines at even lower concentrations.  
Finally, to evaluate the safety profile of xanthohumol female BALB/c mice were fed 
with a xanthohumol enriched diet for three weeks, achieving a daily dose of 
approximately 1000 mg xanthohumol /kg body weight per day. Macroscopical and 
histopathological examination of liver, kidney, colon, lung, heart, spleen and 
thymus revealed no signs of xanthohumol-toxicity, and biochemical serum analysis 
confirmed normal organ function. Further, serum glucose levels and hepatic 
glycogen content as well as hepatic CYP2E1 mRNA expression levels were 
unaffected by xanthohumol treatment. In addition, also mRNA expression of 
several genes indicative of early hepatic inflammation and fibrosis, a hallmark of 
chronic liver injury, did not differ between xanthohumol treated and control mice.  
In conclusion, xanthohumol has the potential to ameliorate NASH induced liver 
injury as well as different pro-tumorigenic mechanisms known to promote HCC 
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progression. Together with the good safety profile these data suggest the potential 
use of xanthohumol as a functional nutrient or therapeutic agent to prevent or treat 
chronic liver diseases like NASH or HCC.  
  3 
2 Introduction 
 
2.1 Hop 
2.1.1 Botany 
The hop plant (Humulus lupulus L.) is well-known as a raw material in the brewing 
industry. The female inflorescences, rich in polyphenolic compounds and acyl 
phloroglucinols are widely used to preserve beer and to give it a characteristic 
aroma and flavor. From a taxonomic point of view, the genus Humulus belongs to 
the family Cannabaceae of the order Urticales, but in 2003 it was incorporated in 
the order Rosales (Van Cleemput et al. 2009, Bremer et al. 2003). Hop is a 
dioecious, wind pollinated, perennial climbing bine. The stems regrow each spring 
from the rhizomes of an underground rootstock and die off each autumn, whereas 
the cold-hardy rootstock itself can reach an age of up to 50 years. The slender, 
flexible, climbing stems twist around their support in a clockwise direction growing 
up to 6-9 m in length, often with stout-hooked hairs. The wire-haired leaves are 
heart-shaped and lobed, on foot-stalks, and placed opposite one another on the 
stem. They are of a dark-green color with their edges coarsely toothed. Blooming 
period ranges from early to mid July. The male inflorescences are loose, panicle-
like cymes. Female inflorescences are cone-shaped spikes of pistillate flowers 
(aments) growing from the axils of the leaves and are also known as hop strobiles, 
hop cones or “hops” (Figure 2.1). They consist of overlapping green ovate bracts 
with a pair of pistillate flowers tucked between each adjacent pair of bracts. 
 
 
Figure 2.1 Development of the female inflorescences of Humulus lupulus from the flower (left) to 
the ripe strobile (right). Pictures from Nagel, 2009 (Nagel 2009). 
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Hop resin a.k.a. lupulin is secreted by glandular trichomes, also called lupulin 
glands, and can be found on the adaxial surfaces of the cone bracts (Figure 2.2). 
 
 
Figure 2.2 (A) Longitudinal section of a hop cone showing lupulin glands at the base of bracteoles. 
(B) A single bract showing trichomes mainly on the lower third of the bract. (C) Ripe lupulin glands. 
Pictures from Nagel, 2009 (Nagel 2009). 
 
2.1.2 Medical use 
Humulus lupulus has a long history as a medicinal remedy to treat a wide range of 
complaints (Zanoli and Zavatti 2008). It has been mainly recommended as a mild 
sedative useful to treat sleeplessness and nervousness (Blumenthal 1998). 
Traditionally, hops were used to treat excitability and restlessness associated to 
tension headache, to improve appetite and digestion and to relieve toothache, 
earache and neuralgia (Barnes et al. 2002; Grieve 1971). In addition hops have 
been reputed to exert diuretic, antispasmodic and anaphrodisiac effects 
(Blumenthal 1998; Duke 1985; Weiss 2009). Native American tribes used hops as 
a sedative, antirheumatic, analgesic and as a diuretic (Blumenthal 1998; Bown 
2001; Hamel and Chiltoskey 1975). Further, they used heated hops as a poultice 
in the treatment of pneumonia (Carr and Westey 1945) and a decoction of hops 
was recommended for intestinal pain and fevers (Bown 2001). In India, the 
Ayurvedic Pharmacopoeia recommends hops to treat restlessness associated with 
nervous tension, headache and indigestion (Karnick 1994). In traditional Chinese 
medicine hops are used to treat insomnia, restlessness, dyspepsia and lack of 
appetite. Alcoholic extracts of hops have been clinically used in China to treat 
leprosy, pulmonary tuberculosis, acute bacterial dysentery, silicosis and 
asbestosis with positive outcomes (Blumenthal et al. 2000). Topically, hops were 
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used to treat crural ulcers and skin injuries and to relieve muscle spasms and 
nerve pain (Lawless 1995). In aromatherapy hops have been used for skin care, 
breathing conditions, nervousness, nerve pain and stress-related conditions 
(Lawless 1995). The Committee on Herbal Medicinal Products (HMPC) of the 
European Medicines Agency (EMEA) reports the traditional use of Humulus 
lupulus flos for relief of mild symptoms of mental stress and insomnia. The 
German Commission E and European Scientific Cooperative on Phytotherapy 
(ESCOP) approved hops as a treatment for excitability, mood and sleep 
disturbances (Blumenthal 1998). 
 
2.1.3 Phytochemistry 
Starting from the second half of the 20th century, several phytochemical studies 
were performed to investigate the composition of hop cones and other parts of the 
plant, leading to the isolation and identification of pharmacologically relevant 
compounds. The main structural classes of chemical compounds identified from 
hop cones include terpenes, bitter acids and chalcones. Hops are also rich in 
flavonol glycosides (kaempferol, quercetin, quercitrin, rutin) (Sagesser and 
Deinzer 1996) and catechins (catechin gallate, epicatechin gallate) (Gorissen et al. 
1968).  
Hundreds of terpenoid components were identified in the volatile oil (0.3–1.0% of 
hop strobile weight): primarily β-caryophyllene, farnesene and humulene 
(sesquiterpenes) and myrcene (monoterpene) (Eri et al. 2000; Malizia et al. 1999). 
The bitter acids (5–20% of hop strobile weight) are phloroglucinol derivatives 
usually classified as α-acids and β-acids. β-acids are structurally different from 
α-acids for one more prenyl group. The bitter acids are present in hops as a 
complex mixture of variable composition and concentrations. The main α-acids are 
humulone (35–70% of total α-acids), cohumulone (20–65%) and adhumulone (10–
15%); the corresponding β-acids are lupulone (30–55% of total β-acids), 
colupulone and adlupulone. In addition to the two series of normal, co- and ad-
homologs, there exist some other minor bitter acids.  
Aside from volatile oil and bitter acids, several prenylated flavonoids were 
identified from hop cones. 
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2.2 Flavonoids 
Flavonoids are widely common products of secondary metabolism in plants, but 
are totally absent in animals, bacteria, fungi and algae. Beside of phenolic acids, 
lignans and stilbens, the flavonoids represent a major part of plant polyphenols. 
The name derives from the Latin word for “yellow” (flavus), which reflects the fact 
that most (but not all) flavonoids have a yellow color. Flavonoids are formed in 
plants from malonate and the aromatic amino acids phenylalanine and tyrosine 
(Harborne 1986). The basic flavonoid structure is the flavane (2-phenylchromane) 
(Figure 2.3), which consists of 15 carbon atoms arranged in three rings; two 
aromatic rings (which are labeled A and B) and an O-heterocyclic C-ring 
(C6−C3−C6 structure). 
2
3
45
6
7
8 O
1 1'
2'
3'
4'
5'
6'
A C
B
 
Figure 2.3 Flavane (2-phenylchromane) 
 
Depending on the level of oxidation and pattern of substitution of the C-ring, 
flavonoids are subdivided into various classes: flavanes, flavanoles (3-hydroxy-
flavanes), flavandioles (3,4-dihydroxy-flavanes), flavanones (4-oxo-flavanes), 
flavones (3-oxo-flav-2-enes), flavonoles (3-hydroxy-4-oxo-flav-2-enes), 
flavanonoles (3-hydroxy-4-oxo-flavanes) and flavylium salts also known as 
anthocyanidines. A special group of flavonoids are the chalcones, which are 
derivatives of phenyl styryl ketone (Figure 2.4). Chalcones are precursors of 
flavanones in the biosynthesis of flavane derivatives.  
 
α
O
1'
6'
5'
4'
3'
2'
β
1
2
3
4
5
6
A B
 
Figure 2.4 Chalcone (phenyl styryl ketone) 
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Prenylated chalcones are the principle component of the phenolic fraction of hops. 
Xanthohumol (XN) (Figure 2.5) is the most abundant chalcone found in hops (0.1–
1% of dry weight) and was first described by Power et al. in 1913 (Power et al. 
1913). Other chalcones can also be found in hops, but they occur at 10 to 100-fold 
lower concentrations. XN accounts for approximately 82−89% of all prenylated 
flavonoids in hops (Rodriguez et al. 2001; Stevens et al. 2003; Stevens and Page 
2004).  
 
α
O
1'
2'
3'
4'
5'
6'
β
1
2
3
4
5
6
OHOCH3
OH
1''
HO
2''
3''
4''
5''  
Figure 2.5 Xanthohumol 
 
Most of the chalcones found in hops contain a free 2’-hydroxy group and can 
therefore isomerize to their corresponding flavanones. XN can be converted to the 
prenylflavanone isoxanthohumol (IX) (Figure 2.6) in consequence of thermal 
treatment (e.g. during the brewing process of beer) or increased pH value 
(Stevens et al. 1999). Due to this, IX is the main prenylflavonoid present in beer. 
 
O
O
OH
OCH3
HO
 
Figure 2.6 Isoxanthohumol 
 
Over the past few years, hop research has been largely dedicated to 
prenylflavonoids in view of their extremely interesting bioactivities. Whereas 
xanthohumol has received much attention mostly as a cancer chemopreventive 
agent, 8-prenylnaringenin (8-PN), an isomerization product of desmethyl-
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xanthohumol (DMX), also present in beer, enjoys fame as the most potent 
phytoestrogen isolated to date, whereas 6-prenylnaringenin (6-PN), another 
isomerization product of DMX shows only slight estrogenic activity (Milligan et al. 
2002; Milligan et al. 2000; Milligan et al. 1999) (Figure 2.7). 
 
O
OHOH
OH
HO
O
6
8 O
OH
OH
HO
O
6
8 O
OH
OH
HO
DMX
8-PN
6-PN
 
Figure 2.7 Desmethylxanthohumol (DMX), 8-prenylnaringenin (8-PN), 6-prenylnaringenin (6-PN) 
 
2.3 Xanthohumol 
Xanthohumol (2’,4’,4-trihydroxy 6’-methoxy 3’-prenyl chalcone) is a structurally 
simple prenylated chalcone. The distribution of xanthohumol (XN) (Figure 2.5) is 
limited to and ubiquitous within Humulus lupulus, respectively. XN is secreted as 
part of the hop resin, which is accumulated in the glandular trichomes (see also 
Figure 2.2). Furthermore, XN can also be found in the trichomes on the underside 
of young leaves. 
 
2.3.1 Dietary exposure 
Beer is the most important dietary source of XN and related prenylflavonoids. The 
average person in Germany consumed 0.31 liters of beer per day in 2006 
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(Statistisches Bundesamt Deutschland, 2007). Based on the assumption that the 
mean XN concentration in beer is 0.03 mg/l (Forster et al. 2002), the daily intake of 
XN would be about 9.3 µg. Compared to the total polyphenol content of beer, the 
fraction of prenylflavonoids is relatively small (Gerhäuser 2005a; Vinson et al. 
2003). Based on this, one might conclude that prenylflavonoids contribute little to 
the antioxidant properties of beer. On the other hand, prenylflavonoids differ from 
other beer polyphenols, such as proanthocyanidins, flavonol glycosides, and 
phenolic acids, in that they are more lipophilic, and therefore, may be more 
effective antioxidants at lipophilic surfaces such as membranes and low-density 
lipoproteins (Stevens et al. 2003; Stevens and Page 2004). 
 
2.3.2 Bioavailability and metabolism 
The metabolism of prenylated flavonoids is not very well documented. The 
biotransformation of flavonoids occurs at several places in the body, but mainly in 
the liver and the gut lumen. Thus, the gut flora might play a significant role as well. 
In general, monomeric flavonoids reach the small intestine unchanged (Spencer 
2003), where absorption from the gut in the mesenteric circulation can take place. 
However, the extent of dietary polyphenol absorption in the small intestine is rather 
limited (10-20%) (Kuhnle et al. 2000; Spencer et al. 1999), thereby implying that a 
large proportion reaches the colon. Incubation of XN with human faecal samples 
or with Eubacterium limosum, a bacterial species occurring in human faeces, 
revealed no transformation of XN by the intestinal microbiota (Possemiers et al. 
2008). Further, Hanske et al. observed no influence on diversity of the intestinal 
microbial flora after oral application of XN to Sprague Dawley rats (Hanske et al. 
2005). 
Several studies showed that flavonoids are mostly excreted as glucuronides in 
humans and animals. Glucuronidation is the most important reaction route for the 
phase II detoxification process for most xenobiotics. This functionalization is 
catalyzed by the membrane-bound UDP-glucuronosyltransferase, mainly in the 
endoplasmatic reticulum of the liver. 
A few studies analyzed the in vitro metabolism of XN using liver microsome 
preparations. Yilmazer et al. studied the biotransformation of XN by rat liver 
microsomes (Yilmazer et al. 2001b). Several metabolites with cyclized and/or 
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oxidized prenyl substituents were described. Aromatic hydroxylation of the B-ring 
of XN was also observed. In a subsequent study, Yilmazer et al. investigated the 
in vitro metabolism of XN by rat and human liver microsomes, respectively, in the 
presence of uridine 5’-diphosphoglucuronic acid (Yilmazer et al. 2001a). Four 
glucuronic acid metabolites were detected by LC–MS, of which the two major 
metabolites were identified as the 4’-O- and 4-O-monoglucuronides of XN 
(approximately 89% and 10%, respectively, of the total glucuronides generated in 
the incubations).  
The biotransformation of XN and IX by human liver microsomes was 
reinvestigated by Nikolic et al. (Nikolic et al. 2005). Six metabolites of XN and 13 
metabolites of IX were identified. The authors described hydroxylation of a prenyl 
methyl group as the primary route of oxidative metabolism of both compounds. 
Importantly, IX was partly demethylated to form 8-PN. This might be relevant for 
the reported estrogenic effect of hop extracts. Further, to mimic reactions that 
could take place in the stomach, XN was incubated with diluted hydrochloric acid, 
and cyclization to the isomeric flavanone IX could be observed (Nikolic et al. 
2005).  
In a study peformed by Nookandeh at al. (Nookandeh et al. 2004), fecal samples 
from 12 female Sprague-Dawley rats were collected 24 and 48 h after a single 
dose application of XN (1000 mg/kg b.w.). XN was largely recovered in unchanged 
form (89% of the total of recovered flavonoids). However, 22 metabolites were 
isolated from the faeces and characterized by spectroscopic methods. 
Biotransformation resulted in the formation of cyclic prenyl moieties that included 
the oxygen at C-4’ or at C-2’ as well as metabolites with non-cyclic oxidized prenyl 
substituents. Further, XN-4’-O-glucuronide, XN-4-O-methyl ether, XN-4-O-acetate, 
IX and an IX metabolites were identified. 
After oral administration of XN to male rats (50 mg/kg b.w.), Yilmazer could detect 
XN in the plasma mainly in form of two mono-glucuronides (4’-O and 4-O-
monoglucuronides) whose maximum concentrations reached 180 and 65 nM after 
4 h (Yilmazer 2001). The cumulative amounts of both XN glucuronides excreted in 
the urine reached a plateau at 12 h after oral XN administration and accounted for 
0.3% and 0.05% of the administered dose, respectively. The recovery of 
unchanged XN from the urine was 0.2%. Other metabolites of XN, formed by 
cytochrome P450 enzymes, were detected in plasma and urine samples at much 
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lower levels than the glucuronides. These findings suggest that XN’s 
bioavailability, defined as the fraction of the administered dose that is ultimately 
absorbed intact, is very low. 
Pharmacokinetics of XN in male Wistar rats were also investigated by Avula and 
co workers (Avula et al. 2004). In a first experiment, rats received either oral or 
intravenous administration of a low dose of XN (20 mg/kg b.w.). In a second 
experiment, rats received a single oral administration of up to 500 mg XN/kg b.w. 
Plasma, urine, and faeces were collected at varying time points and assayed for 
their XN content by HPLC. XN and its metabolites were excreted mainly in faeces 
within 24 h of administration. Plasma levels of XN fell rapidly within 60 min after 
i.v. administration. At these doses, no XN was detected in plasma after oral 
administration. 
 
2.4 Biological effects of xanthohumol 
2.4.1 Anti-inflammatory effects 
The transcriptional factor NFκB plays a key role in regulating immune responses 
and cell survival. Incorrect regulation of NFκB has been linked to cancer and 
inflammation. A decrease in NFκB activity is mainly considered as having anti-
inflammatory and pro-apoptotic effects. NFκB consists of a heterotrimer composed 
of two members of the RelA family, mainly p50 and p65. In its inactive form NFκB 
is bound in the cytoplasm to members of the IκB family, and here mostly, to IκBα. 
Proinflammatory stimuly lead to rapid phosphorylation of IκBα by the protein 
kinase complex IKK. The phosphorylation of IκBα leads to its ubiquitination and 
rapid degradation that consequently frees the p50-p65 NFκB heterodimer to 
translocate to the nucleus and to activate NFκB-dependent genes 
(Vallabhapurapu and Karin 2009; Wong and Tergaonkar 2009). 
Immunofluorescent staining done by Albini et al. (Albini et al. 2006) showed that 
NFκB was largely localized in the cytoplasm of unstimulated HUVEC (Human 
Umbilical Vein Endothelial Cells), and that XN treatment had little effect on this 
localization. Treatment with 10 ng/ml TNF for 15 min resulted in translocation of 
NFκB to the nucleus. However, pretreatment with 10 µM XN completely inhibited 
NFκB activation and translocation. Western blot analysis indicated that XN 
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significantly repressed the levels of phosphorylated IκBα present in HUVEC after 
stimulation with TNF, indicating an inhibitory effect on IKK. 
Colgate et al. determined the NFκB activity in nuclear extracts of prostate 
epithelial cells and showed that treatment with 20 mM XN resulted in a 42% 
decrease of NFκB activity (Colgate et al. 2007). Further, Monteiro et al. described 
inhibitiory effects of XN on NFκB activity in vivo in a murine cancer model 
(Monteiro et al. 2008).  
In a study performed by Gerhäuser et al. (Gerhäuser et al. 2002) XN exhibited 
anti-inflammatory potential by inhibition of cyclooxygenase (COX) activity with IC50 
values of 16.6 µM for the constitutive form of cyclooxygenase COX-1 and 41.5 µM 
for the inducible COX-2, which is linked to inflammation as well as to 
carcinogenesis and angiogenesis. Cyclooxygenases convert arachidonic acid to 
prostaglandin H2 which is the precursor of prostanoids (prostaglandins, 
prostacyclin and thromboxanes). The latter play important roles as mediators of 
inflammation.  
XN also suppressed the protein expression of the inducible nitric oxide synthase 
(iNOS) in LPS-stimulated murine macrophages which leads to decreased nitric 
oxid (NO) release (Zhao et al. 2003; Zhao et al. 2005). NO acts as a signal for a 
variety of cellular functions throughout the body, including the triggering of 
inflammation and dilatation of blood vessels. Kim et al. described a binding 
interaction of iNOS and COX-2 (Kim et al. 2005). iNOS inhibitors, which also 
inhibit COX-2 activation, may decrease pro-inflammatory prostaglandin formation 
in a synergistic way. 
In a recently published study by Gao et al., XN revealed immunosuppressive 
effects on T cell proliferation, development of IL-2 activated killer cells and 
cytotoxic T lymphocytes as well as on production of Th1 cytokines (IL-2, IFN-γ and 
TNF). These effect were caused, at least in part, due to inhibition of NFκB through 
suppression of phosphorylation of ΙκBα (Gao et al. 2009). 
 
2.4.2 Anti-angiogenic effects 
Angiogenesis exhibits a critical role in the progression of cancer. Solid tumors 
smaller than 1 to 2 mm³ are not vascularized, however, to spread they need to be 
supplied by blood vessels that deliver oxygen and nutrients and remove metabolic 
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waste, respectively. Beyond the critical volume of 2 mm³, oxygen and nutrients 
have difficulty diffusing to the cells in the center of the tumor, causing a state of 
cellular hypoxia that marks the onset of tumoral angiogenesis (Sooriakumaran and 
Kaba 2005). In addition to its role in tumor growth, (neo)vascularization influences 
the dissemination of cancer cells, eventually leading to metastasis formation. 
Prostaglandins are also known to initiate formation of new blood vessels 
(angiogenesis), an important pathophysiological mechanism of tumor growth. 
Furthermore, excessive and prolonged NO generation promotes the production of 
vascular endothelial growth factor (VEGF), a known inducer of angiogenesis. 
Considering the studies of Zhao et al. (inhibition of iNOS protein expression) and 
Gerhäuser et al. (inhibition of COX activity), mentioned in the previous chapter 
(2.4.1), anti-angiongenic effects of XN could be assumed (Gerhäuser et al. 2002; 
Zhao et al. 2003; Zhao et al. 2005).  
Indeed, a study of Albini et al. (Albini et al. 2006) showed the ability of XN to 
significantly inhibit angiogenesis in a matrigel sponge implanted to mice by adding 
XN to the drinking water at concentrations as low as 2 µM. At higher 
concentrations (up to 200 µM) XN displayed a more marked inhibition of 
angiogenesis without any detectable adverse effects on animal health parameters. 
Bertl at al. could show that XN effectively inhibited microcapillary formation of 
human microvascular endothelial cells on a membrane matrix at XN-doses of 1, 5 
and 10 µM, respectively, whereas at a dose of 0.1 µM, some tubes started to form 
within the incubation period of 6 h (Bertl et al. 2004). In another study performed 
by Bertl, an inhibition of angiogenesis (33% in comparison with controls) in female 
immuno-deficient mice implanted with human breast tumor xenograft was reported 
after subcutane injection of XN at the daily dose of 1000 mg/kg b.w. for 14 days 
(Bertl 2005). In a similiar in vivo experiment oral administration of XN to nude mice 
inoculated with breast cancer cells resulted in decreased tumor microvessel 
density. Anti-angiogenic effects of XN were further confirmed by immunoblotting 
for Factor VIII expression, a marker for active endothelial cells, in XN-treated and 
untreated tumors (Monteiro et al. 2008). 
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2.4.3 Anti-cancerous effects 
One of the mechanisms through which XN may exhibit anti-cancerous effects is 
anti-angiogenic activity. Indeed, the studies performed by Bertl (Bertl 2005), Albini 
et al. (Albini et al. 2006) and Monteiro et al. (Monteiro et al. 2008) mentioned in the 
previous chapter (2.4.2 Anti-angiogenic effects), showed that XN exerts anti-
cancerous effects in vivo. The growth of human breast tumor xenograft implanted 
in immuno-deficient mice was significantly inhibited (inhibition by 83% compared to 
controls) by subcutaneous  injection of XN at the daily dose of 1000 mg/kg b.w. for 
14 days (Bertl 2005). Oral administration of XN (20 µM in the drinking water) 
significantly inhibited the growth rate of Kaposi's sarcoma cells in male nude mice 
(Albini et al. 2006). Furthermore, Monteiro et al. observed positive effects of orally 
applied XN (100 µM in the drinking water) in immuno-deficient mice inoculated 
with breast cancer cells, i.e. central necrosis within tumors, reduced inflammatory 
cell number, increased percentage of apoptotic cells and decreased microvessel 
density (Monteiro et al. 2008). As anti-cancerous mechanisms the anti-angiogenic 
properties but also the NFκB inhibiting effects of XN were discussed.  
 
A common strategy of cancer cells to evade apoptosis is to upregulate NFκB 
activity (Shen and Tergaonkar 2009). Thus, NFκB inhibitors like XN may have 
beneficial effects in cancer treatment and prevention. Colgate et al. described 
inhibitory effects of XN on NFκB activity in benign prostate hyperplasia cells 
(Colgate et al. 2007). Pro-apoptotic effects as well as a loss of viability in both 
benign prostate hyperplasia cells and prostate cancer cells were observed. In 
general, the various anti-inflammatory effects of XN described in chapter 2.4.1 
may contribute to its anti-cancerous effects. Epidemiological studies have 
established that many tumors occur in association with chronic infectious 
diseases, and it is also known that persistent inflammation increases the risk, and 
accelerates the development of cancer, respectively (Berasain et al. 2009). 
 
In addition to the anti-angiogenic and anti-inflammatory effects of XN also other 
XN-mediated effects may contribute to its anti-cancerous properties. 
Plazar et al. and Kac et al. described antigenotoxic/antimutagenic effects. XN 
efficiently protected human hepatoma cells against the genotoxic effects of the two 
pro-carcinogens 2-amino-3-methylimidazo[4,5-f]quinoline and benzo(a)pyrene 
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which are both found in cooked meat and are dependent on cytochrome P450 
mediated metabolic activation (Kac et al. 2008; Plazar et al. 2008; Plazar et al. 
2007). In line with these studies, Miranda et al found that XN prevents the 
metabolic activation of 2-amino-3-methylimidazo[4,5-f]quinoline most likely due to 
inhibition of cytochrome P450 enzymes, in particular Cyp1A2 (Henderson et al. 
2000; Miranda et al. 2000c). XN also inhibits activity of Cyp1A1 and Cyp1B1, but 
not Cyp2E1 and Cyp3A4 at low micromolar concentrations as shown by 
Henderson et al. (Henderson et al. 2000). These cytochrome P450 enzymes form 
a group of enzymes (phase 1 enzymes) that mediate the metabolic activation of 
many chemical carcinogens, and the inhibitory effects of XN may offer an 
explanation for the reported inhibitory effects of beer on mutagenesis and DNA 
adduct formation induced by carcinogens (Arimoto-Kobayashi et al. 1999).  
 
In addition to inhibition of phase 1 enzymes, the activation of phase 2 enzymes 
represents another target for cancer chemoprevention. These enzymes are 
responsible for detoxification of xenobiotics including carcinogens. Phase 2 
enzymes mediate the conjugation of xenobiotics to endogenous ligands, such as 
glutathione, glucuronic acid, acetate and sulfate, to facilitate excretion. 
NAD(P)H:quinone reductase is a phase 2 enzyme that is involved in the 
detoxification of quinones by reductive conversion into hydroquinones, which are 
suitable substrates for enzymatic conjugation. Quinone reductase activity in 
cultured mouse hepatoma cells was significantly induced by XN at a dose of 
approximately 2 µM (Dietz et al. 2005; Miranda et al. 2000a), and Gerhäuser et al. 
characterized XN as a monofunctional inducer, that is, it selectively induces 
quinone reductase without simultaneously causing transcriptional activation of the 
phase 1 enzyme Cyp1A1 (Gerhäuser et al. 2002).  
 
Furthermore, XN seems to affect not only development but also the progression of 
cancers. In two different invasion assays with breast cancer cells a significant anti-
invasive effect of XN at a dose of 5 µM could be demonstrated by Vanhoecke et 
al. (Vanhoecke et al. 2005a). As a mechanism, involvement of the 
E-cadherin/catenin invasion-suppressor complex could be identified. In addition, a 
XN-mediated (5 µM) stimulation of aggregation, which could be completely 
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inhibited by an antibody against E-cadherin, was observed (Vanhoecke et al. 
2005a).  
 
Apparently, XN seems to affect several different pro-cancerogenic processes, and 
hence, appears as a broad-spectrum chemopreventive agent. Further, it exhibits 
these effects on a variety of cancer cells regardless of the origin of the cancer. 
Interestingly, the effective dose seems to vary depending on the type of cancer. 
Lust et al. and Dell’Eva et al. described anti-proliferative (IC50 values between 2.5 
and 10 µM XN) and cytotoxic (approx. 25 µM XN) effects of XN on various 
leukemia cell lines (Dell'Eva et al. 2007; Lust et al. 2005). A similar result was 
obtained in a study by Gerhäuser et al. (Gerhäuser et al. 2002). Here, the growth 
inhibitory effect of XN on leukaemia cells (IC50 value of 3.7 µM) was accompanied 
by an induction of nonspecific acid esterase expression, a marker for cell 
differentiation. In the same study, treatment of mammary adenocarcinoma cells 
with 25 µM XN decreased proliferation to approximately 40% compared to control 
cells. Pan et al. observed anti-proliferative effects of XN on human colon cancer 
cells in concentrations lower than 10 µM (Pan et al. 2005). Monteiro et al. reported 
significant anti-proliferative and cytotoxic effects of XN on a breast cancer cell line 
in doses of 1 µM and 50 µm, respectively (Monteiro et al. 2008). XN-mediated 
growth inhibition of prostate cancer cell lines (IC50 values of approx. 13 µM XN) 
were described by Delmulle at al. (Delmulle et al. 2006; Delmulle et al. 2008), 
whereas Miranda et al. found inhibited proliferation of breast and ovarian cancer 
cells with IC50 values of 13 and 0.52 µM XN, respectively (Miranda et al. 1999).  
 
One explanation for the anti-proliferative effects of XN in various fast replicating 
cancer cells could be the XN-mediated inhibition of human DNA polymerase α 
activity (IC50 value of 23 µM) and/or on DNA topoisomerase I activity described by 
Gerhäuser et al. (Gerhäuser et al. 2002) and Lee et al. (Lee et al. 2007), 
respectively. 
 
Some studies point to a particularly effective anti-cancerogenic effect of XN under 
hypoxic conditions. Thus, proliferation and motility of human fibrosarcoma cells 
was significantly suppressed in the presence of XN at a dose of 3 µM under 
hypoxic, but not under normoxic conditions (Goto et al. 2005). Hypoxia is an 
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important feature of the microenvironment of a wide range of solid tumours (Airley 
and Mobasheri 2007; Rademakers et al. 2008).  
 
In summary, anti-angiogenic, anti-inflammatory and antigenotoxic/antimutagenic 
effects, anti-invasive and anti-proliferative effects in cancer cells, and inhibition of 
cytochrome P450 enzymes (phase 1 enzymes) together with induction of phase 2 
enzymes should result in enhanced protection against carcinogenesis and 
carcinoma progression. 
 
Aside from direct effects on cancer cells also other effects of XN may be useful for 
cancer treatment. Lee et al. could demonstrate that XN clearly decreases the 
mRNA levels of the drug efflux genes ABCB1 (MDR1), ABCC1 (MRP1), ABCC2 
(MRP2), and ABCC3 (MRP3), which are known to be responsible for drug 
resistances (Lee et al. 2007). 
 
Finally, also the antioxidant properties of XN should be mentioned when 
evaluating its chemopreventive potential (see next chapter). 
 
2.4.4 Antioxidant properties 
Many flavonoids exhibit antioxidant properties (Lotito and Frei 2004; Lotito and 
Frei 2006; Pietta 2000). Scavenging of reactive oxygen species (ROS; hydroxyl, 
peroxyl, and superoxide anion radicals) represents one of the mechanisms by 
which flavonoids exert their antioxidant activities. Free radicals can initiate 
reactions that modify polyunsaturated lipids, proteins and nucleic acids, which 
have been associated with the early stages of atherosclerosis and carcinogenesis, 
and with the development of neurodegenerative diseases (Stevens and Page 
2004). Scavenging of ROS by XN was studied by Gerhäuser et al. (Gerhäuser et 
al. 2002), who found that XN was approximately 3 and 9-fold more potent than the 
reference compound trolox (a water soluble vitamin E analogue) at a concentration 
of 1 µM with respect to scavenging of hydroxyl and peroxyl radicals, respectively, 
in the ORAC (oxygen radical absorbance capacity) fluorescein assay (Davalos et 
al. 2004). XN was also shown to scavenge superoxide anion radicals, generated 
by xanthine oxidase, without directly inhibiting xanthine oxidase activity. 
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Furthermore, XN inhibited superoxide anion radical formation by 12-O-
tetradecanoylphorbol-13-acetate stimulation in differentiated human promyelocytic 
leukemia cells with an IC50 of 2.6 µM (Gerhäuser et al. 2002). In studies performed 
by Vogel et al. a trolox equivalent antioxidative capacity of 2.3 was determined for 
XN (Vogel and Heilmann 2008; Vogel et al. 2008). Miranda et al. could show that 
prenylated chalcones from hops protect low density lipoproteins (LDL) from Cu2+-
induced oxidation in vitro. At a concentration of 5 µM XN decreased conjugated 
diene formation, a marker of lipid peroxidation, by more than 70% (Miranda et al. 
2000b). Similarly, inhibitory effects of XN on liver microsomal lipid peroxidation, 
induced by Fe2+-ascorbate, Fe3+-ADP/NADPH, or tert-butyl hydroperoxide, could 
be seen (Rodriguez et al. 2001). Further, XN showed high total oxygen radical 
absorbance capacity as well as singlet oxygen absorbance capacity (Yamaguchi 
et al. 2009). In a study by Plazar et al. hepatoma cells pre-treated with XN (1 µM 
for 20 min) revealed significantly reduced levels of tert-butyl hydroperoxide-
induced DNA strand breaks, indicating that its protective effect is mediated by 
induction of cellular defense mechanisms against oxidative stress (Plazar et al. 
2007). 
 
2.4.5 Anti-infective properties 
Serveral anti-infective properties of XN are described. Thus, XN acts as a broad 
spectrum anti-infective agent against Gram-positive bacteria (Staphylococcus 
aureus, Streptococcus mutans), viruses (cytomegalovirus, herpes simplex virus 
type 1 and 2, human immunodeficiency virus 1), fungi (Trichophyton spp.) and 
malarial protozoa (Plasmodium falciparum) (Gerhäuser 2005b). However, the 
mechanisms of the observed inhibitory activities are still under investigation. 
 
2.4.5.1 Anti-bacterial effects 
Mizobuchi and Sato (Mizobuchi and Sato 1984) investigated the potential of XN to 
inhibit the growth of Gram-positive Staphylococcus aureus, a pathogen often 
found in pneumonia and sepsis, in comparison to the antibiotic activity against 
E. coli. A minimal inhibitory concentration (MIC) of 17.7 µM was determined for 
XN, whereas no antiproliferative effect on E. coli could be seen. Bhattacharya et 
al. (Bhattacharya et al. 2003) tested XN against three strains of Streptococcus in a 
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disc diffusion assay. XN demonstrated antimicrobial activity against S. mutans, 
one of the causative agents of dental caries, S. salivarius and S. sanguis. At a 
dose of 50 µg per disc, XN produced similar zones of inhibition against all three 
strains as thymol, a well-known additive to popular mouthwashs. The lowest 
concentration to prevent visible bacterial growth was determined in a turbidity 
assay. At a pH of 7.5, XN inhibited the growth of S. mutans with an MIC of 35 µM. 
When the pH was lowered to 6.5 by addition of ascorbic or hydrochloric acid, the 
MIC of XN decreased to a concentration as low as 6 µM. 
 
2.4.5.2 Anti-fungal effects 
Investigations on anti-fungal activity of hop constituents are limited. Mizobuchi and 
Sato (Mizobuchi and Sato 1984) tested XN against five human pathogenic fungi, 
i.e. Trichophyton mentagrophytes, Trichophyton rubrum, Candida albicans, 
Fusarium oxysporum and Mucor rouxianus. With a MIC of 8.8 µM XN inhibited the 
growth of the dermatophytic fungi T. mentagrophytes and T. rubrum more 
efficiently than the positive control griseofulvin (MIC 17.8 µM), Isoxanthohumol 
was basically inactive. Also, weak inhibition of M. rouxianus was observed (MIC 
141 µM XN). C. albicans and the opportunistic human pathogen F. oxysporum 
were not responsive to XN. 
 
2.4.5.3 Anti-malarial effects 
Malaria is caused by infection with Plasmodium falciparum. Chalcones are among 
the structural classes for which antiplasmodial activity has been reported and are 
thought to act against malarial cysteine proteases which are responsible for 
haemoglobin degradation (Li et al. 1995; Liu et al. 2001). The malarial aspartyl and 
cysteine proteases represent promising targets for the development of anti-
malarial compounds (Li et al. 1995; Steele et al. 2002). Herath et al. determined 
the anti-malarial activity of XN against the chloroquine-sensitive Plasmodium 
falciparum strain D6 and the chloroquine-resistant strain W2 (Herath et al. 2003). 
Plasmodial lactate dehydrogenase activity was measured as an indicator of the 
number of parasites remaining in infected red blood cells. XN was active against 
both strains, with IC50 values of approximately 9 µM against strain D6, and 3 µM 
against strain W2, respectively. Anti-malarial activity was confirmed in a study by 
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Frölich et al. (Frölich et al. 2005). In vitro antiplasmodial activity of XN was 
evaluated against the chloroquine-sensitive strain poW and the multiresistant 
clone Dd2, using a 3H-hypoxanthine incorporation assay. In addition, the influence 
on glutathione-dependent haemin degradation was analyzed (Frölich et al. 2005). 
Inhibited haemin degradation leads to a decrease of parasite replication by the 
subsequent accumulation of toxic by-products. XN showed activity with IC50 values 
of 8 µM (poW) and 24 µM (Dd2), respectively. For comparison, chloroquine was 
tested as a positive control, and IC50 values of 0.015 and 0.14 µM were 
determined in the two strains, respectively.  
 
2.4.5.4 Anti-viral effects 
XN was shown to possess anti-viral activity against a series of DNA and RNA 
viruses (Gerhäuser 2005b).  
In a study performed by Wang et al. (Wang et al. 2004), the potential of XN to 
inhibit various steps essential for the replication of HIV-1 was tested. During 
replication, many viruses destroy not only the infected host cells but also 
neighbouring uninfected cells by cytopathic effects. XN was able to inhibit HIV-1-
induced cytopathic effects, as well as the production of viral p24 antigen and 
reverse transcriptase activity as indicators of active retroviral replication, with IC50 
values of 2.3, 3.6 and 1.4 µM, respectively, in lymphocytes infected with HIV-1IIIB. 
Further, XN inhibited HIV-1 replication in peripheral blood mononuclear cells with 
an IC50 value of approx. 60 µM. The activity of recombinant HIV-1 reverse 
transcriptase and HIV-1 entry into cells were not inhibited. From these results it 
was concluded that the targets of XN on HIV-1 may be situated post reverse 
transcription. 
Buckwold et al. tested XN against a series of DNA and RNA viruses in vitro 
(Buckwold et al. 2004). Bovine viral diarrhea virus (BVDV) as a surrogate model of 
hepatitis C virus and human rhinovirus (HRV) were included as RNA viruses. 
Further, the DNA herpes viruses cytomegalovirus (CMV) as well as herpes 
simplex virus types 1 and 2 (HSV-1 and -2) were utilized to assess anti-viral 
activity. Inhibitory effects of XN against BVDV, HRV, HSV-1 and HSV-2 were 
tested using cell-based assays designed to assess inhibition of cytopathic effects. 
CMV was tested in a plaque reduction assay. XN inhibited the growth of BVDV, 
CMV, HSV-1 and HSV-2 more potently than its isomerization product 
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isoxanthohumol. Half-maximal inhibitory concentrations of XN to inhibit viral 
replication were in the range of 4–8 µM. Concomitantly, the half-maximal toxic 
concentrations (TC50) to reduce the number of viable host cells used to propagate 
the viruses were about 3 to 6-fold higher than the IC50 values and ranged from 17–
25 µM. XN did not have any anti-viral activity against HRV. In the same study, an 
XN-enriched extract was tested. XN contained in the extract appeared to account 
for almost all of the anti-viral activity of the extract, since the therapeutic indices 
(TI = TC50/IC50) of pure XN against BVDV, HSV-1 and HSV-2 were similar to those 
of the XN-enriched extract.  
 
2.4.6 (Anti)estrogenic potential 
Hop extracts have repeatedly been reported to possess estrogenic properties 
(Chadwick et al. 2006). Gerhäuser et al. investigated the pro- and antiestrogenic 
properties of XN and isoxanthohumol (IX) in Ishikawa cells. This human 
endometrial cancer cell line responds to estrogens with elevated alkaline 
phosphatase activity (Holinka et al. 1986a; Holinka et al. 1986b; Holinka et al. 
1986c). Concomitant treatment with estrogens and test compounds allows the 
identification of estrogenic as well as antiestrogenic effects. XN efficiently inhibited 
estrogen-mediated induction of alkaline phosphatase without possessing intrinsic 
estrogenic potential, whereas IX was identified as a weak estrogen agonist 
(Gerhäuser et al. 2002). XN and IX revealed very low affinity for both estrogen 
receptors (ERα and ERβ) in competitive receptor binding assays (Milligan et al. 
2000). In addition, inhibiting effects of XN on human recombinant aromatase 
(CYP19) activity was described by Gerhäuser et al. (Gerhäuser 2005a), and 
therefore, XN might reduce endogenous estrogen levels. 
Possemiers et al. have discovered that intestinal microbiota are able to transform 
IX efficiently into 8-prenynaringenin (8-PN) (Possemiers et al. 2008; Possemiers et 
al. 2006; Possemiers et al. 2005). 8-PN has been identified as one of the most 
potent phytoestrogens (Milligan et al. 2002; Milligan et al. 1999). Hence, the 
antiestrogenic XN may exhibit an estrogenic effect only indirectly through its 
isomeric IX. 
Vanhoecke et al. could detect no differences in uterotrophic activity in mice after 
4 weeks of treatment with XN, which was added to the drinking water in a 
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concentration of 0.5 mM. Furthermore, no chances in circulating estradiol and 
progesteron concentrations could be measured (Vanhoecke et al. 2005b). In a 
toxicity study performed by Hussong et al., no alteration of plasma testosterone 
levels could be detected in Sprague Dawley rats after 4 weeks of treatment with 
XN at high daily doses of up to 1000 mg/kg b.w. (Hussong et al. 2005). These data 
suggest that XN do not exhibit (anti)estrogenicity in vivo. 
 
2.4.7 Effects on lipid and carbohydrate metabolism 
Casachi et al. examined the role of XN on apolipoprotein B (apoB) and triglyceride 
(TG) synthesis and secretion, using hepatoma cells as model system (Casaschi et 
al. 2004). The results indicated that XN decrease apoB secretion in a dose-
dependent manner under both basal and lipid-rich conditions (decrease by approx. 
40% at a dose of 15 µM XN). This decrease was associated with increased 
cellular apoB degradation. Furthermore, XN inhibited the synthesis of TG in the 
microsomal membrane and the transfer of this newly synthesized TG to the 
microsomal lumen (decreases of approx. 25 and 60%, respectively, under lipid-
rich conditions). TG availability is a major factor in the regulation of apoB 
secretion. The inhibition of TG synthesis was caused by a reduction in 
diacylglycerol acyltransferase (DGAT) activity, which was corresponded to a 
decrease in DGAT-1 mRNA expression, but not DGAT-2 expression. DGAT is a 
key enzyme in TG synthesis. In addition, XN decreased microsomal TG transfer 
protein (MTP) activity in a dose-dependent manner. MTP may also control the rate 
of TG transfer from the microsomal membrane to the active lumenal pool. Whether 
TG accumulation in the microsomal lumen is predominantly reduced due to DGAT 
or MTP activity could not be determined. These results were also confirmed by 
Tabata et al., who could show that XN inhibited DGAT activity in rat liver 
microsomes with an IC50 value of 50 µM (Tabata et al. 1997). Goto et al. described 
increased synthesis of TGs and formation of lipid droplets in the cytoplasm of 
human fibrosarcoma cells induced by hypoxic conditions, however, the treatment 
of XN (3 µM) downregulated the TG synthesis and completely canceled the 
appearance of lipid droplets (Goto et al. 2005). Nozawa et al. could demonstrate 
that XN ameliorates lipid and glucose metabolism in KK-Ay mice which 
spontaneously develop severe obesity, hyperlipidemia and insulin resistance 
Introduction  23 
(Iwatsuka et al. 1970; Nozawa 2005). XN-fed KK-Ay mice exhibited lowered levels 
of plasma glucose as well as plasma and hepatic triglyceride levels. Further, they 
showed a decreased water intake, lowered weights of white adipose tissue, and 
increased levels of plasma adiponectin, indicating that XN attenuated diabetes in 
KK-Ay mice. Additionally, lowered expression levels of the sterol regulatory 
element-binding protein-1c gene SREBP-1c, including its targets involved in fatty 
acid synthesis, as well as lowered expression levels of gluconeogenetic genes 
could be noticed. The authors suggested that XN may act as a farnesoid X 
receptor (FXR) ligand.  
Yang et al. and Mendes et al. described effects of XN on preadipocytes and 
mature adipocytes respectively (Mendes et al. 2008; Yang et al. 2007). XN inhibits 
differentiation of preadipocytes and induces apoptosis in mature adipocytes which 
both leads to a decreased number of adipocytes. 
 
2.4.8 Effects on bone resorption 
Tobe et al. reported inhibiting effects of XN on bone resorption with an IC50 value 
of about 1 µM assessed in a so-called osteoclast pit assay (Boyde et al. 1984; 
Tobe et al. 1997). However, the underlying mechanism remains unclear. 
 
2.5 Xanthohumol safety studies 
So far, two safety studies have been performed, one in mice and one in rats with 
in part discrepant results. 
Vanhoecke et al. treated female C3H mice orally with XN by adding it to the 
drinking water (0.5 mM XN) (Vanhoecke et al. 2005b) resulting in a daily dose of 
approx. 30-35 mg XN/kg body weight. After 4 weeks, analysis of various 
haematological and biochemical blood parameters did not reveal significant 
differences. Furthermore, no signs of liver toxicity, as indicated by aspartate 
transferase, lactate dehydrogenase and of cholestasis, as indicated by alkaline 
phosphatase activities, were noticed after treatment. Also, no indications of 
myolysis were found by creatine kinase activity measurements. Amylase and 
lipase activities excluded toxicity in the exocrine pancreas, while blood urea 
nitrogen and creatinine concentrations suggested an intact kidney function. 
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Further, the metabolism of carbohydrates (glucose, insulin, glucagon, 
haemoglobin A1c), lipids (cholesterol, triglycerides), proteins and uric acid was not 
disturbed. As mentioned in chapter 2.4.6, the data related to uterotrophic activity 
and concentrations of circulating estradiol and progesterone suggest that XN is 
also devoid of (anti)estrogenicity in vivo. Levels of free thyroxin and 
triiodothyronine indicate that the thyroid function was not affected by the treatment. 
In a second study, Hussong et al. could demonstrate that treatment with 
100 mg/kg b.w. XN per day did not affect either fertility or mating and nursing 
abilities of Sprague Dawley rats (Hussong et al. 2005). Also development of the 
XN treated rats’ offspring was not different from control rats’ offspring. 
Furthermore, at daily doses of up to 1000 mg/kg b.w. no changes in relative 
weights of kidney, lung, heart, stomach, and spleen as well as in total body 
weights were noticeable. However, a decrease in relative liver weight and hepatic 
glycogen content, assessed by histological investigation, was described. The 
authors interpreted these findings as suggestive of mild hepatotoxicity, but it could 
be also caused by an altered carbohydrate metabolism (see chapter 2.4.7). The 
concentrations chosen in this toxicity study were actually considered as maximum 
tolerable doses to detect potentially harmful effects of XN. Generally, it is unlikely 
that animals or humans are naturally exposed to XN doses that high under normal 
circumstances. 
Several other in vivo studies have been performed with markedly lower XN 
concentrations (Albini et al. 2006; Avula et al. 2004; Hanske et al. 2005; Monteiro 
et al. 2008) except for the studies of Nookandeh et al. (Sprague Dawley rats 
received single dose of approx. 1000 mg XN/g b.w. by gavage) (Nookandeh et al. 
2004) and Nozawa et al. (KK-Ay mice were fed with a XN enriched diet resulting in 
a daily XN uptake of approx. 1000 mg XN/g b.w. for 4 weeks) (Nozawa 2005). In 
none of these studies any adverse side effects of XN have been reported, but it 
has to be taken into account that these studies were not designed for identifying 
any adverse effects of XN. 
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2.6 Effects of xanthohumol on the liver 
The liver is the largest gland in the human body and plays a major role in 
metabolism. It has a number of functions in the body, including regulation of 
carbohydrate and lipid metabolism, the production of bile, hormones and 
coagulation factors, production and decomposition of red blood cells, plasma 
protein synthesis, vitamin storage, detoxification and others. 
The tissue of the liver consists of about 94% (v/v) parenchymal cells which are 
called hepatocytes and about 6% (v/v) non-parenchymal cells. Hepatocytes are 
the main functional cells of the liver. The non-parenchymal cell fraction can be 
subdivided into Kupffer cells (macrophages of the liver), liver sinusoidal endothelial 
cells (LSEC), liver-resident lymphocytes, cholangiocytes, hepatic stellate cells and 
some minor fractions. Hepatic stellate cells (HSC) account for about 10% of non-
parenchymal cells and are the main storage site for retinoids (40-70% of the body 
reserves). They are located in the perisinusoidal space (space of Disse; see 
Figure 2.8), located between hepatocytes and sinusoidal endothelial cells (Pinzani 
1995). 
 
 
Figure 2.8 Schematic structure of the liver sinusoidal endothelium. Liver sinusoids are lined by liver 
sinusoidal endothelial cells (LSEC), which separate the sinusoid lumen from hepatocytes. Kupffer 
cells patrol the sinusoids and bind to LSEC and occasionally hepatocytes through the gaps of two 
adjacent LSEC. Hepatic stellate cells are located in the space of Disse. Figure from Bertolino et al., 
2002 (Bertolino et al. 2002). 
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2.6.1 Effects of oral administered xanthohumol on the liver 
The only study which described in vivo effects of oral administered XN on liver 
relevant parameters is the study performed by Hussong et al. (Hussong et al. 
2005), mentioned in chapter 2.5. The described decrease of the relative liver 
weights and glycogen content could be seen only after feeding very high amounts 
of XN (1000 mg/kg b.w. per day). At a 10-fold lower dose, no differences in relative 
liver weights could be detected. None of the other studies, in which XN was fed to 
either mice or rats mention any adverse effects of XN (Albini et al. 2006; Avula et 
al. 2004; Nookandeh et al. 2004; Nozawa 2005; Vanhoecke et al. 2005b). As 
described in chapter 2.4.7, Nozawa et al. detected lowered levels of hepatic 
triglycerides in XN treated obese mice (Nozawa 2005), which may be linked to the 
inhibitory effect of XN on diacylglycerol acyltransferase and microsomal 
triglyceride transfer protein described by Casachi et al. and Tabata et al. (see 
chapter 2.4.7) (Casaschi et al. 2004; Tabata et al. 1997). 
 
2.6.2 Effects of xanthohumol on hepatocellular carcinoma cells 
Despite the extensive research on anticancer functions of XN, very few studies 
have evaluated the inhibitory effects of XN on hepatocellular carcinoma (HCC), but 
it has been reported that several other flavonoids from plants, including apigenin, 
luteolin and isoliquiritigenin, have anti-HCC effects (Chiang et al. 2006; Hsu et al. 
2005; Lee et al. 2005). Exposure of the human hepatoma cell line HepG2 to XN 
concentrations of up to 10 µM for 24 h did not affect cell viability, determined by 
Plazar et al. using the MTT assay (Plazar et al. 2007). Exposure to 50 µM or 
100 µM XN, however, reduced the cell viability by almost 50 and 85%, 
respectively, compared to untreated control cells. Similar results were found by 
Dietz et al. (Dietz et al. 2005) with Hepa 1c1c7 cells, a mouse hepatoma cell line. 
In a crystal violet toxicity assay an IC50 of 30 µM (referred to cell survival) has 
been determined. Ho et al. studied the pro-apoptotic effects of XN on two human 
HCC cell lines and one nonmalignant murine hepatoma cell line in vitro (Ho et al. 
2008). The human HCC cell lines HA22T/VGH and Hep3B were more sensitive to 
XN than the murine nonmalignant hepatoma cell line AML12, as indicated in their 
IC50 values assessed in a cell viability assay. The IC50 values for HA22T/VGH and 
Hep3B were 166 µM and 108 µM, respectively. For AML12 cells a significantly 
Introduction  27 
higher IC50 of 211 µM has been determined. Further, treatment with 90 µM XN for 
4 h resulted in 9.6 and 24.7% apoptotic cells in HA22T/VGH and Hep3B, 
respectively, determined by Annexin V-EGFP staining. No Annexin V-positive cells 
could be found in the AML12 cell line under the same conditions.  
2.6.3 Effects of xanthohumol on hepatocytes 
Only one study described the effects of XN on (nonmalignant) primary 
hepatocytes. Rodriguez et al. tested the effects of eight flavonoids (including XN) 
on tert-butyl hydroperoxide (TBH) treated primary cultures of rat hepatocytes 
(Rodriguez et al. 2001). XN and four other flavonoids reduced cytotoxic effects of 
0.5 µM TBH, an inducer of lipid peroxidation, at concentrations of both 5 and 
10 µM. Higher concentrations were not tested because some of the flavonoids 
revealed cytotoxic effects on primary rat hepatocytes at concentrations of 25 µM 
by themselves. Unfortunately, it remains unknown to the reader, which of the eight 
tested flavonoids exhibits the observed cytotoxicity. 
Thus far, there existed no published data concerning the effects of XN on primary 
human hepatocytes (PHH). 
 
2.6.4 Effects of xanthohumol on non-parenchymal liver cells 
Up until now, studies describing the effects of XN on hepatic stellate cells, Kupffer 
cells, sinusoidal endothelial cells or other liver-specific non-parenchymal cells 
were missing. 
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2.7 Liver diseases 
2.7.1 Definition and natural course of liver disease 
Liver diseases can be divided into acute and chronic liver diseases. Intoxications 
or acute infections may lead to acute liver injury. Due to the high regeneration 
capacity of the liver such conditions rarely lead to complete liver failure. In these 
cases, liver transplantation is often the only therapeutic option. Fortunately, 
complete liver failure caused by acute injury is a rare condition. However, the main 
health problem and burden worldwide are chronic liver diseases. Here, regardless 
of the etiology, persistence of hepatic injury leads to chronic hepatic inflammation 
which can lead to liver fibrosis and ultimatively cirrhosis. 
 
2.7.2 Liver fibrosis 
Hepatic fibrosis can be looked upon as an exuberant wound healing process in 
which excessive connective tissue builds up in the liver (Bataller and Brenner 
2005; Friedman 2003). The extracellular matrix (ECM), composed of collagen, 
elastin, structural glycoproteins, proteoglycans and some minor components, is 
either overproduced, degraded deficiently, or both. The trigger is chronic injury, 
especially, if there is an inflammatory component.  
The main causes of liver fibrosis in industrialized countries include chronic HCV 
(see chapter 2.7.5.4.3) infection, alcohol abuse, and non-alcoholic steatohepatitis 
(NASH) (discussed later in chapter 2.7.5.5).  
Fibrosis itself causes no symptoms but can lead to portal hypertension (the 
scarring distorts blood flow through the liver), cirrhosis and liver cancer. The main 
liver cells that produce ECM proteins are hepatic stellate cells (HSC), first 
described by von Kupffer in 1876 (Benyon and Arthur 1998; Burt 1993; Gabele et 
al. 2003). HSC are the central mediators of hepatic fibrosis in chronic liver disease 
(Bataller and Brenner 2005; Friedman 2008; Friedman 2004). HSC reside in the 
space of Disse and are the major storage sites of vitamin A (see also previous 
chapter 2.6). Following chronic liver injury, HSC proliferate, loose vitamin A and 
undergo a major phenotypical transformation to α-smooth muscle actin (α-sma) 
positive myofibroblasts (activated HSC) acquiring contractile, proinflammatory, and 
fibrogenic properties (Marra 1999; Milani et al. 1990) (Figure 2.9).  
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Figure 2.9 Changes in the hepatic architecture (A) associated with advanced hepatic fibrosis (B). 
Following chronic liver injury, inflammatory lymphocytes infiltrate the hepatic parenchyma. Some 
hepatocytes undergo apoptosis, and Kupffer cells get activated, releasing fibrogenic mediators. 
HSC proliferate and undergo a dramatic phenotypical activation, secreting large amounts of 
extracellular matrix proteins. Sinusoidal endothelial cells lose their fenestrations, and the tonic 
contraction of HSC causes increased resistance to blood flow in the hepatic sinusoid. Figure from 
Bataller and Brenner, 2005 (Bataller and Brenner 2005). 
 
Activated HSCs migrate and accumulate at the sites of tissue repair, secreting 
large amounts of ECM and regulating ECM degradation. They produce a wide 
variety of collagenous and non-collagenous ECM proteins, building up fibrous scar 
tissue. Subsequently, this fibrous tissue can be remodeled through digestion by 
matrix metalloproteinases (MMPs). In turn, the digestion of matrix is controlled 
through the inhibition of MMPs by tissue inhibitors of matrix metalloproteinases 
(TIMPs) of which TIMP-1 is of major importance. In a healthy liver, the synthesis 
(fibrogenesis) and breakdown (fibrolysis) of matrix tissue are in balance. In chronic 
liver injury collagen types I, III, and IV are all increased. However, the increase of 
type I collagen is predominant, and therefore, its ratio to types III and IV is 
increased as well (Burt et al. 1990; Hahn et al. 1980; Rojkind et al. 1979; Seyer et 
al. 1977). Collagen synthesis in HSC is regulated at transcriptional and 
posttranscriptional levels (Lindquist et al. 2000). Increased collagen mRNA 
stability mediates the increased collagen synthesis in activated HSCs (Lindquist et 
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al. 2004; Stefanovic et al. 1997). Furthermore, activated HSC are characterized by 
increased proinflammatory gene expression and resistance to apoptosis (Bataller 
and Brenner 2005; Friedman 2004). It could be shown that NFκB plays a critical 
role in HSC activation (Elsharkawy et al. 2005; Hellerbrand et al. 1998a; 
Hellerbrand et al. 1998b). Increased hepatic NFκB activity is known to promote 
hepatic inflammation and fibrosis in chronic liver diseases (Elsharkawy and Mann 
2007). 
Liver fibrosis is now recognized to be a dynamic process that can progress or 
regress over periods as short as months (Friedman 2003; Hofmann and Zeuzem 
2003; Soyer et al. 1976). The possibility of reversing the fibrosis is an essential 
issue for developing therapeutic approaches, since most liver diseases are not 
clinically present until reaching an advanced fibrotic stage.  
As fibrotic liver diseases advance, disease progression from collagen bands to 
bridging fibrosis to frank cirrhosis occurs. 
 
2.7.3 Liver cirrhosis 
The accumulation of ECM proteins in progressive liver fibrosis distorts the hepatic 
architecture by forming a fibrous scar, and the subsequent development of 
nodules of regenerating hepatocytes defines cirrhosis. Cirrhosis produces 
hepatocellular dysfunction and increased intrahepatic resistance to blood flow, 
which both result in hepatic insufficiency and portal hypertension, respectively 
(Gines et al. 2004). This condition can cause further symptoms like fluid build-up in 
the abdomen (called ascites), build-up and bleeding of esophageal varices, 
muscle wasting, bleeding from the intestines, easy bruising, enlargement of the 
breasts in men (called gynaecomastia), and a number of other symptoms. 
Ultimatively, cirrhosis leads to a loss of liver function (decompensated cirrhosis), a 
condition with high morbidity and mortality. 
Further, liver cirrhosis is the main risk factor for the development of hepatocellular 
carcinoma (HCC).  
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2.7.4 Liver cancer 
Liver cancer implies all types of cancers located in the liver. Most of them are 
metastatic cancers (secondary liver cancers). Primary liver cancers (cancers that 
started in the liver) can be subdivided into different types of cancer, namely 
hepatocellular carcinoma (HCC), hepatoblastoma and cholangiocarcinoma (bile 
duct cancers). Tumors of the blood vessels located in liver are also known 
(angiosarcoma, hemangiosarcoma and hemangioendothelioma). 
 
2.7.4.1 Hepatocellular cancer 
2.7.4.1.1 Prevalence and incidence 
Hepatocellular carcinoma (HCC) is a highly malignant disease with an extremely 
poor prognosis. It is the most common primary malignant tumor of the liver and 
accounts for approximately 90% of primary liver cancers (El-Serag et al. 2008; El-
Serag and Rudolph 2007). Relative to other malignant diseases, HCC ranks fifth in 
overall frequency, causing almost one million deaths annually and its mortality is 
third among all cancers, behind only lung and colon cancer (Kubicka et al. 2000; 
Villanueva et al. 2007). In most countries, especially Western countries, the 
incidence of HCC is still rising (Deuffic et al. 1998; El-Serag and Mason 1999; El-
Serag et al. 2001; Kubicka et al. 2000; Stroffolini et al. 1998; Taylor-Robinson et 
al. 1997). Furthermore, the distribution of patients with HCC has shifted toward 
relatively younger ages, with the greatest increases occurring between the ages of 
45 and 60 years (Villanueva et al. 2007). In Germany, HCC ranks seventh to 
eighth in frequency, but it is the tumor with the highest increase of incidence 
(Kubicka et al. 2000). 
 
2.7.4.1.2 Etiology 
HCC pathogenesis is a multi-step process that involves genetic and epigenetic 
events occurring during initiation and progression of the disease. The genetic 
basis of hepatocarcinogenesis is still poorly understood. HCC develops in almost 
80% of cases on a cirrhotic liver (Minguez et al. 2009), mostly caused by chronic 
HBV or HCV infection, chronic alcohol abuse or non-alcoholic steatohepatitis 
(NASH) (Villanueva et al. 2007). Further, exposure to aflatoxins is an important 
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contributor to the high incidence of liver cancer in tropical areas of the world, 
where contamination of food grains with the fungus Aspergillus fumigatus is 
common. There is a multiplicative interaction between aflatoxin exposure and 
chronic infection with HBV, suggesting that the carcinogenic mechanisms differ 
(Parkin 2001). 
 
2.7.4.1.3 Therapy and prognosis 
Despite some new promising drugs like multi-kinase inhibitors, HCC still has a 
very poor prognosis. Without specific treatment, the median survival time for 
patients with early and advanced tumors are 6-9 months and 1-2 months, 
respectively. (Bosch and Munoz 1989; Kew 2002; Lau and Lai 2008). Early 
diagnosis and treatment could significantly improve the prognosis, but HCC is 
frequently diagnosed at advanced stages, since early stages of HCC causes no or 
only little symptoms. Curative resection of HCC is possible (Hoofnagle 2004), 
however, the success of this approach is limited because in most cases the liver is 
cirrhotic, and there is a high rate of tumor recurrence or development of new 
tumors, respectively (Llovet et al. 2004). Liver transplantation has become a 
frequently used alternative, but it is not possible for all patients, and in a significant 
number of cases HCC reoccur in the transplanted liver (Schlitt et al. 1999), to 
some extent promoted by the post-transplantational immunosuppressive therapy 
(Buell et al. 2005). Local ablative therapies are increasingly being used to treat 
HCC, either as definitive therapy or as an intermediate step in patients awaiting 
liver transplantation. Transarterial chemoembolization (TACE) has been shown to 
increase survival in a randomized controlled trial (Llovet et al. 2002). Further, 
percutaneous ethanol injection (PEI) has been proven to be relatively easy to 
perform, and this procedure is inexpensive (Lencioni et al. 2004). 
 
2.7.5 Causes for chronic liver diseases 
Several mechanisms and diseases, respectively, may cause chronic hepatic 
inflammation, chronic liver damage and eventually liver failure, if fibrosis 
progresses, resulting in complete cirrhosis and loss of hepatic function. 
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2.7.5.1 Alcohol induced liver disease 
Since the liver is responsible for metabolism of alcohol (ethanol), drugs and 
environmental toxins, prolonged exposure to any of these agents can cause 
hepatitis.  
Thus, alcoholic liver disease (ALD) is still one of the most frequent causes for 
chronic liver disease, at least in Western countries (Barve et al. 2008; Bergheim et 
al. 2005). The quantity of alcohol consumed, the frequency with which it is 
consumed, and the pattern of consumption, respectively, determine the likelihood 
of developing ALD. There are no official guidelines for “sensible drinking” in 
Germany, but maximum doses of 3 standard drinks/day (men) and 2 standard 
drinks/day (women), respectively, are recommended as “low risk” alcohol 
consumption. In Germany, a standard drink is defined as a drink containing about 
12 g of ethanol (AIM - Alcohol in Moderation 2009). Binge drinking, which is 
considered as being more harmful than frequent but moderate drinking due to the 
high peaks of blood alcohol concentration (BAC), is defined as consuming five or 
more drinks (men) or four or more drinks (women), respectively, in approximately 
2 h (National Institute on Alcohol Abuse and Alcoholism 2004). This rate of 
drinking will elevate BAC to 0.08% on average (Li 2008). Even more harmful, 
heavy drinking is defined as frequent drinking of five or more drinks by men and 
four or more drinks by women per day. In addition to increasing the risk of 
developing alcohol-use disorders (AUD; alcohol abuse and alcohol dependence), 
excessive, long-term (chronic) alcohol consumption can cause a variety of adverse 
health effects, much of these derived from damage to inner organs, including 
alcoholic liver disease, alcoholic pancreatitis, impaired brain structure and 
function, and cardiomyopathy. Excessive drinking is also associated with an 
increased risk for cancers of the oropharynx, esophagus, and liver, and can 
exacerbate the health consequences of infection with hepatitis C, HIV and other 
infectious agents.  
Even moderate alcohol consumption can promote development of a fatty liver. 
Although the alcoholic fatty liver is reversible with abstinence, the degree of 
steatosis, especially when associated with alcoholic hepatitis, predisposes to 
fibrosis and cirrhosis in subjects who continue to drink (Teli et al. 1995). The risk of 
cirrhosis increases proportionally with daily alcohol consumption above a daily 
threshold of 30 g (Bellentani et al. 1997). It is presumed that other factors such as 
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sex, genetic background, and environmental influences, including chronic viral 
infection, play a role in the genesis of ALD (Becker et al. 1996; Bode et al. 1995; 
Wilfred de Alwis and Day 2007). Approximately 10 to 35% of heavy drinkers 
develop alcoholic hepatitis, and 10 to 20% develop cirrhosis (National Institute on 
Alcohol Abuse and Alcoholism 1993).  
 
2.7.5.2 Drug induced liver injury 
Further, drug induced liver injury has emerged as a major cause of acute liver 
failure (ALF) and has become a leading reason for removal or restriction of 
approved drugs by regulatory agencies (Fontana 2008; Navarro and Senior 2006; 
Ostapowicz et al. 2002; Watkins 2005). Drug-induced ALF accounts for 
approximately 20% of ALF in children (Murray et al. 2008). The percentage is even 
higher in adults (Murray et al. 2008). Although most patients experience milder 
drug-induced hepatotoxic reactions such as moderate hepatitis, cholestasis, or 
asymptomatic enzyme elevation, it is important to recognize the potential for 
progression to ALF. Further, drug intake may exacerbate liver inflammation and/or 
fibrosis initially caused by other factors.  
The most common cause of drug-induced ALF is acetaminophen, followed by 
antituberculotic, antiepileptic and antibiotic drugs. Most drugs cause liver injury 
infrequently. These reactions are considered idiosyncratic, occurring at therapeutic 
doses from 1 in every 1000 patients to 1 in every 100,000 patients, with a pattern 
that is consistent for each drug or drug class. However, a few drugs such as 
acetaminophen directly damage hepatocytes in a dose-dependent fashion (Lee 
2003).  
 
2.7.5.3 Autoimmune related mechanisms and genetic defects 
Further, autoimmune related mechanisms and genetic defects may cause liver 
inflammation and chronic damage. For example, primary sclerosing cholangitis is 
an autoimmune disease affecting the bile ducts, while in primary biliary cirrhosis 
small bile ducts are affected. Gilbert's syndrome is a genetic disorder of the 
bilirubin metabolism, and there are genetically induced glycogen storage diseases. 
Wilson’s disease is a hereditary disorder leading to hepatic accumulation of 
copper. In hemochromatosis, a defect of the HFE gene leads to increased iron 
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uptake, and conseqently, increased hepatic iron accumulation. The latter is one of 
the most frequent monogenetic diseases in Caucasians.  
 
However, besides hemochromatosis and alcoholic liver disease, the most frequent 
causes of chronic liver diseases are infections with hepatitis viruses and non-
alcoholic stetaohepatitis. 
 
2.7.5.4 Viral hepatitis 
Hepatitis viruses have been named in the order of their discovery as hepatitis A, B, 
C, D, and E. Most relevant are hepatitis A, B and C. 
2.7.5.4.1 Hepatitis A  
Infection with the hepatitis A virus (HAV) occurs via faecal and oral transmission 
(i.e. by excrements) or by contaminated food. There is an effective vaccination 
against hepatitis A viruses that can prevent infection. In developing countries, and 
in regions with poor hygiene standards, the incidence of infection with this virus is 
high. In industrialized countries the infection is contracted primarily by susceptible 
young adults, most of whom are infected with the virus during trips to countries 
with a high incidence of the disease. Normally the infection processes without 
typical symptoms, and therefore, often remains unnoticed. In some cases an acute 
infection develops with symptoms like fatigue, nausea, absence of appetite, fever, 
vomiting, dark color of faeces and yellow color of the skin. In few cases (~1%), 
hepatitis A can take a severe course and may eventually lead to fulminant hepatic 
failure. The hepatitis A infection never takes a chronic course. Patient which have 
recovered from hepatitis A infection are protected against a new HAV infections. 
 
2.7.5.4.2 Hepatitis B 
The hepatitis B virus (HBV) can be transmitted by both sexual contact and blood. 
Furthermore, vertical transmission is the main route of transmission in regions with 
high HBV incidence. HBV is very infectious, but a safe vaccination is available and 
can efficiently prevent transmission. Acute hepatitis B infection occurs without 
specific symptoms in the majority of cases. Similar to hepatitis A, symptoms like 
fatigue, nausea, absence of appetite, fever, vomiting, dark colored faeces and 
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yellow color of the skin may occur. One third of patients develop an acute 
inflammation of the liver with more severe symptoms lasting several months (acute 
hepatitis B). In few cases (~1%), acute hepatitis B can take a severe course with 
fulminant hepatic failure. Complete cure of the infection leads to life long immunity. 
However, in 5% of adult patients the virus remains in the body and the infection 
takes a chronic course. Chronic hepatitis B also processes with unspecific 
symptoms in most cases. Fatigue and loss of motivation are frequent, but also 
symptoms of influenza, like aching muscles or joints, can appear. Approximately, 
one third of patients with chronic hepatitis B will develop liver cirrhosis, and 
eventually, liver cancer. 
 
2.7.5.4.3 Hepatitis C 
Main transmission route of hepatitis C virus (HCV) is direct blood contact (due to 
needle stick injury or intravenous drug consumption etc.), and in fewer cases also 
sexual contact. Further, vertical transmission may lead to infection. So far, there is 
no vaccination against hepatitis C. Acute hepatitis C normally processes without 
specific symptoms. Influenza like symptoms, fatigue, nausea, absence of appetite 
and pain in upper abdomen can appear. An acute HCV infection is diagnosed 
rarely. In most cases hepatitis C takes a chronic course, i.e. the virus remains in 
the body and causes a continuous inflammation of the liver. Mostly, chronic 
hepatitis C is mild and without clear disturbances. Main symptoms can be fatigue, 
loss of motivation and joint pain. Chronic forms of hepatitis C cause an enduring 
damage of the liver which leads to liver fibrosis, cirrhosis and liver cancer in a 
significant number of patients. 
 
2.7.5.5 Non-alcoholic fatty liver disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) plays a more and more important role, 
and is today considered as the most frequent liver disease in Western countries.  
 
2.7.5.5.1 Definition 
Non-alcoholic fatty liver disease (NAFLD) was first described by Ludwig et al. 
(Ludwig et al. 1980) and is defined as a spectrum of diseases ranging from hepatic 
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steatosis without inflammation to hepatic steatosis with an inflammatory 
component (non-alcoholic steatohepatitis; NASH) without or with progredient 
fibrosis. The latter may progress to cirrhosis and HCC (Figure 2.10). 
 
fatty liver non-alcoholicsteatohepatitis (NASH)
with or without fibrosis
liver cirrhosis
(promoting tumorigenesis)
steatosis hepatis inflammation(& fibrosis)
cirrhosis
( liver cancer)
 
Figure 2.10 The spectrum of NAFLD: fatty liver (steatosis hepatis), non-alcoholic steatohepatitis 
(NASH) with or without fibrosis, and liver cirrhosis, which promotes development of liver cancers. 
 
Overall, the histology as well as several other pathophysiological changes mimic 
alcoholic liver disease, although NAFLD and non-alcoholic steatohepatitis (NASH) 
develop per definitionem in the absence of chronic alcohol abuse (Anstee and 
Goldin 2006).  
 
2.7.5.5.2 Prevalence of NAFLD/NASH 
NAFLD is the most common cause of chronic liver disease in Western countries 
(Clark et al. 2002). Estimates of the prevalence of NAFLD in unselected 
populations from developed countries vary between 20 and 30% (Browning et al. 
2004; Jimba et al. 2005; Marcos et al. 2000; Ruhl and Everhart 2004), and 
approximately 2-3% of the same population will have NASH (Neuschwander-Tetri 
and Caldwell 2003).  
The prevalence of liver steatosis increases with increasing body weight (Andersen 
et al. 1984; Bellentani et al. 2000) and is estimated to be 65-75% in obese 
individuals (BMI > 30 kg/m²) (Angulo 2002; Bellentani et al. 2000) and even 85-
90% in morbidly obese individuals (BMI > 35 kg/m²) (Andersen et al. 1984; Angulo 
2002). In accordance, the vast majority of individuals with NAFLD are either 
overweight (BMI > 25 kg/m²) or obese (BMI > 30 kg/m²) (Bacon et al. 1994). 
Furthermore, in obese individuals, the prevalence of NASH increases 
disproportionately, and more than half of NASH patients have Type 2 diabetes 
mellitus and up to 80% reveal dyslipidaemia (Cortez-Pinto and Camilo 2004).  
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The overall prevalence of NAFLD in children is estimated at 3-10%, but it may be 
much higher in obese children (Shneider et al. 2006), and prevalence of obesity in 
children is rapidly increasing (Daniels et al. 2009; Ogden et al. 2006; Strauss and 
Pollack 2001).  
NAFLD is strongly associated with insulin resistance (IR). Development of NAFLD 
is promoted by IR as well as NAFLD promotes IR. NAFLD is now believed to be 
the hepatic manifestation of the metabolic syndrome, which includes central 
obesity, insulin resistance, dyslipidemia, and hypertension (Powell et al. 1990; 
Sanyal 2002). 
 
2.7.5.5.3 Etiology and pathogenesis 
In recent years, there have been significant advances in the understanding of 
mechanisms that contribute to disease progression in NAFLD/NASH. The 
development of NAFLD/NASH is determined by the interaction of genetic and 
environmental factors (Day 2002). 
In 1998 Day and James proposed the ‘two-hit’ hypothesis for the pathogenesis of 
NASH (Day and James 1998). The ‘first hit’ involves an imbalance in fatty acid 
metabolism that leads to hepatic lipid accumulation (steatosis) which sensitizes 
the liver to the induction of inflammation by a second pathogenic insult (‘second 
hit’) that promotes oxidative stress and dysregulated cytokine production and 
hence steatohepatitis. The ‘two-hit’ model has subsequently been revised in 
recognition that a combination of ‘second hits’ (both environmental and genetic) 
may lead to the development of steatohepatitis (Day 2002). The causes for 
progression to fibrosis or even cirrhosis in some NASH patients are subject of 
many studies and are often referred to as the ‘third hit’. 
 
2.7.5.5.4 Prognosis and therapy 
In general, the prognosis for simple steatosis is very good; however, NASH can 
progress to cirrhosis and hepatocellular carcinoma in 10-15% of patients. Once 
cirrhosis is present, it is estimated that 30-40% of these patients will progress to a 
liver-related death over a 10-year period (Bacon et al. 1994; Matteoni et al. 1999; 
Powell et al. 1990). 
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There is no established treatment for NAFLD except for weight loss and treating 
(each component of) the metabolic syndrome.  
 
2.7.5.5.5 Experimental NASH models 
Several mouse models are available to study the mechanisms involved in NALFD, 
which mimic the phenotypic abnormalities known from human liver diseases 
(Anstee and Goldin 2006). The use of genetic defects or targeted overexpression 
of specific genes to produce obesity or impaired hepatic lipid metabolism in 
rodents have been used as NAFLD models (Chen et al. 1996). Although these 
genetic manipulations can assess the biological importance of each gene in vivo, 
they might not reflect the natural etiology of NAFLD in patients and rarely lead to 
the pathology of NASH. Other models frequently used are based on nutritional 
manipulations, e.g. feeding of sucrose-rich and/or fat-rich diets (Surwit et al. 1995). 
However, in most of these models, rodents accumulate only minimal fat and 
develop merely subtile inflammation of the liver. A commonly used model to study 
the pathogenesis of NASH is feeding a methionine-choline deficient (MCD) diet to 
mice or rats. This treatment induces significant hepatic steatosis, inflammation and 
fibrosis similar as seen in human NASH. However, this diet leads to a rapid body 
weight loss, and therefore, does not reflect the situation mostly found in NASH 
patients, i.e. obesity and insulin resistance. 
Recently, a new dietary based model was described (Matsuzawa et al. 2007): the 
so-called Paigen-diet contains 15% cocoa butter, 1.25% cholesterol and 0.5% 
sodium cholate and was originally designed to induce atherosclerosis in rodents 
by the group of Beverly Paigen in 1985 (Paigen et al. 1985). Interestingly, 
atherosclerosis and NASH share in large part the same pathogenetic causes, and 
there is a large overlap of NASH and atherosclerosis patients. In fact, 
NAFLD/NASH seems to promote development of atherosclerosis (Loria et al. 
2008; Sookoian and Pirola 2008; Targher and Arcaro 2007). With regards to the 
liver, it could be observed that rodents fed with the Paigen-diet developed liver 
steatosis, and later on, liver inflammation and fibrosis (Jeong et al. 2005). 
Matsuzawa et al. systematically investigated the effects of the Paigen-diet on the 
liver and lipid/carbohydrate metabolism, respectively, in mice and demonstrated 
that the Paigen-diet is a suitable NASH model including progression of hepatic 
fibrosis (Matsuzawa et al. 2007).  
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2.8 Aim of the thesis 
The aim of this thesis was to analyze the effects of XN on liver diseases with an 
emphasis on NASH and HCC. Here, once the Paigen-diet as a murine NASH 
model was used. Further, in vitro experiments with different primary liver cells and 
HCC cells were performed. Finally, the safety profile of orally applied XN was 
investigated in mice. 
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3 Materials and Methods 
 
3.1 Chemicals and Reagents 
Agarose SeaKem® LE Biozym, Hess/Oldendorf, Germany 
β-Mercaptoethanol Sigma, Deisenhofen, Germany 
Fatty acid free BSA Sigma, Hamburg, Germany 
Ciprobay Bayer, Leverkusen, Germany 
Collagenase type IV Sigma, Hamburg, Germany 
Diflucan Pfizer, Karlsruhe 
DMEM medium PAA Laboratories, Cölbe, Germany 
DMSO Sigma, Deisenhofen, Germany 
Edelstoff Augustiner Bräu, Munich, Germany 
FCS (fetal calf serum) PAN-Biotech, Aidenbach, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
Nonidet® P40 Roche Diagnostics, Mannheim, Germany 
Palmitic acid Sigma, Hamburg, Germany 
Penicillin Invitrogen, Karlsruhe, Germany 
Propidium iodide Sigma, Deisenhofen, Germany 
Streptomycin Invitrogen, Karlsruhe, Germany 
TNF (human) R&D, Wiesbaden-Nordenstadt, Germany 
TNF (murine) R&D, Wiesbaden-Nordenstadt, Germany 
Trypsin/EDTA PAA Laboratories, Cölbe, Germany 
Xanthohumol Alexis Biochemicals, Lausen, Switzerland 
 
All chemicals not listed were purchased at VWR (Darmstadt, Germany). 
 
3.2 Laboratory expendables 
CryoTube vials Nunc, Roskilde, Denmark 
Pipet tips  
(10, 20, 100 und 1000 µl) 
Eppendorf, Hamburg, Germany 
Falcon tubes (50 ml) Corning, New York, USA 
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glassware (various) Schott, Mainz, Germany 
Multiwell plates Corning, New York, USA 
Pipettes (stripettes®) 
(5, 10, 25, 50 ml) 
Corning, New York, USA 
Reaction vessels (1.5 and 2 ml) Eppendorf, Hamburg, Germany 
Scalpels (No. 11) Pfm, Cologne, Germany 
Strip tubes (0.2 ml) Peqlab, Erlangen , Germany 
Cell culture flasks T25, T75, T175 Corning, New York, USA 
 
3.3 Laboratory instruments 
Heating block: 
Thermomixer comfort  
 
Eppendorf, Hamburg, Germany 
PCR-cycler: 
GeneAmp® PCR System 9700 
 
Applied Biosystems, Foster City, USA 
Pipettes: 
Gilson (P2, P20, P200, P1000) 
 
Gilson, Bad Camberg, Germany 
Pipette controllers:  
Accu-jet® 
 
Brand, Wertheim, Germany 
Shaking devices: 
KS 260 Basic Orbital Shaker  
 
IKA® Werke, Staufen, Germany 
Power Supplies: 
Consort E145 
Power Supply-EPS 301 
 
Peqlab, Erlangen, Germany 
Amersham Biosiences, Munich, Germany 
Spectrophotometer: 
EMax® Microplate Reader 
SPECTRAFluor Plus 
 
MWG Biotech, Ebersberg, Germany 
Tecan, Männedorf, Switzerland 
Scale: 
MC1 Laboratory LC 620 D 
 
Sartorius, Göttingen, Germany 
Water bath: 
Haake W13/C10 
 
Thermo Fisher Scientific, Karlsruhe, Germany 
Centrifuge: 
Biofuge fresco 
Megafuge 1.0 R  
 
Heraeus, Hanau , Germany 
Heraeus, Hanau, Germany 
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Microscope: 
Olympus CKX41 with 
ALTRA20 soft imaging system 
 
Olympus Hamburg, Germany 
 
3.4 Buffers 
PBS-Puffer 
 
140 mM NaCl 
10 mM KCl 
6.4 mM Na2HPO4 
2 mM   KH2PO4   pH 7.4 
 
TE-Puffer 
 
10 mM  Tris/HCl 
1 mM   EDTA   pH 8.0 
 
3.5 Cell Culture 
3.5.1 Cell culture medium 
DMEM (high glucose/10%FCS) 4.5 g/l  Glucose  
300 µg/ml  L-Glutamine 
Supplemented with: 
10% (v/v) FCS  
400 U/ml  Penicillin  
50 µg/ml  Streptomycin 
 
HSC medium DMEM (high glucose/10%FCS) 
Supplemented with: 
10 µg/ml  Diflucan  
4 µg/ml  Ciprobay  
 
Freezing medium 5 Vol  DMEM (highgluc./10%FCS) 
3 Vol  FCS 
2 Vol  DMSO 
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3.5.2 Cultivation of cell lines 
All cell culture work was conducted within a laminar flow biosafety cabinet (Hera 
Safe, Heraeus, Osterode, Germany). The cells were cultivated in a Binder series 
CB incubator (Binder, Tuttlingen, Germany) in 10% CO2 atmosphere at 37 °C. 
DMEM containing 4.5 g/l glucose and 300 µg/ml L-glutamine supplemented with 
10% (v/v) FCS, 400 U/l penicillin and 50 µg/ml streptomycin was used as cell 
culture medium. For cell passaging adherent cells were washed with PBS and 
detached with trypsin (0.05%)/EDTA (0.02%) (PAA Laboratories, Cölbe, Germany) 
at 37 °C. Trypsination was stopped by addition of D MEM containing 10% FCS. 
Subsequently, cells were centrifuged at 500 g for 5 min and the obtained cell pellet 
was resuspended in fresh culture medium and distributed to new cell culture flasks 
achieving a cell density thinning factor of 5 to 10. Medium change took place every 
second day. Cell growth and morphology were controlled and documented with a 
microscope (Olympus CKX41 with ALTRA20 Soft Imaging System, Olympus, 
Hamburg, Germany). Cell culture waste was autoclaved before disposal with a 
Sanoclav autoclave (Wolf, Geislingen, Germany). 
 
3.5.3 Human hepatocellular carcinoma cell lines 
The hepatocellular carcinoma cell lines HepG2 (ATCC HB-8065) and Huh7 
(JCR B0403) were obtained from the American Type Culture Collection (ATCC) 
and the Japanese Collection of Research Biosources (JCRB), respectively. 
 
3.5.4 Isolation of primary human hepatocytes 
Primary human hepatocytes (PHH) were isolated in co-operation with the Center 
for Liver Cell Research (Department of Surgery, University of Regensburg, 
Germany) from human liver resections using a modified two-step 
EGTA/collagenase perfusion procedure (Hellerbrand et al. 2008; Hellerbrand et al. 
2007; Pahernik et al. 1996; Ryan et al. 1993; Weiss et al. 2002). The experimental 
procedures were performed according to the guidelines of the charitable state 
controlled foundation HTCR, with the informed patient's consent. For cell isolation 
only tissue which has been classified as not pathological after macroscopical and 
microscopical investigation was used. All used liver resections have been 
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negatively tested for HBV, HCV and HIV infection. Viability of the isolated 
hepatocytes was determined by trypan blue exclusion, and cells with a viability 
greater than 85% were used for further tests. 
 
3.5.5 Isolation of primary murine hepatocytes 
Primary murine hepatocytes (PMH) were isolated from mice by the two-step 
collagenase method of Seglen with minor modifications (Seglen 1976).  
 
Used buffers: 
Perfusion buffer 
 
8 g/l  NaCl 
0.4 g/l  KCl 
90 mg/l Na2HPO4 x 7H2O 
60 mg/l  KH2PO4 
1 g/l  Dextrose 
0.19 g/l EGTA   pH 7.3 
 
Digestion buffer 
 
Perfusion buffer 
Supplemented with: 
0.04%  Collagenase type IV 
  Collagen digestion activity: 
  440 units/mg solid collagenase 
1.5 mM CaCl2 
 
First, mice were anesthetized with ketamine/xylazine according to the guidelines of 
the Central Animal Facility (ZTL) of the University of Regensburg (Germany) 
(Central Animal Facility (ZTL) of the University of Regensburg 2009). Ketamine 
and xylazine was purchased from the Central Animal Facility (ZTL) of the 
University of Regensburg (Germany). The abdomen was opened by median 
incision 1-2 cm above the hind legs up to the sternum, followed by a horizontal 
incision on each side, ending at the rib cage (Figure 3.1 A,B).  
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sternum
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A B
 
Figure 3.1 Anesthetized animal with (A) delineated cutting lines or (B) opened abdomen. 
 
Vena cava inferior (IVC) and portal vein were ligated loosely with sterile threads 
(Figure 3.2 A,B). A 22 GA catheter (Optiva 2, Medex Medical, Klein-Winterheim, 
Germany) was inserted into the portal vein and fixed by tightening the portal vein 
ligation.  
 
portal vein
vena cava inferior
open
thorax
perfused
liver
cathether
A B
 
Figure 3.2 (A) Open abdomen with ligated portal vein and vena cava 
inferior. (B) Perfused liver with cathether connected to the portal vein. 
 
Cathether was connected to the perfusion system composed of a water bath 
adjusted to 37°C and an ISMATEC pump with appropria te flexible tubings 
(Novodirect, Kehl/Rhein, Germany). At first, the liver was perfused with perfusion 
buffer for 3 min at a flow rate of 8 ml/min. Immediately after starting the perfusion, 
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the IVC was cut below the ligation to prevent a pressure build-up in the liver. After 
1 min of perfusion, thorax was opened, the heart was cut and the IVC ligation was 
tightened. After 3 min of perfusion liver was perfused for further 6 min with 
digestion buffer. Thereafter, liver was explanted, briefly washed with PBS and 
minced into small pieces. Gall bladder was removed prior to that. Minced liver was 
taken up in 45 ml cold perfusion buffer and filtered through nylon gaze (Sigma, 
Hamburg) to remove undigested and connective tissue, respectively. Liver cell 
suspension was transferred into 50 ml culture tubes and centrifuged at 30 g for 
3 min (4 °C) to separate hepatocytes (pellet) from non-parenchymal cells 
(supernatant). Pelleted hepatocytes were washed two times by resuspending them 
in perfusion buffer and subsequent centrifugation (30 g, 3 min, 4 °C). Finally, the 
pellet was taken up in 30 ml of GIBCO HepatoZYME-SFM (Invitrogen, Carlsbad, 
CA). The viability of the final cell suspension was checked by trypan blue 
exclusion (see chapter 3.5.7); purity was analyzed by microscopical investigation. 
Cells with a viability greater than 80% and a non-parenchymal cell contamination 
less than 2% were used for further tests. PMH were seeded in 2 ml GIBCO 
HepatoZYME-SFM supplemented with 2 mmol/l L-glutamine, penicillin (100 IU/ml), 
and streptomycin (100 mg/ml) (all from PAA, Pasching, Austria) on type I collagen 
coated plastic dishes (BD Bioscience, Bedford, USA) with a density of 5.0 x 104 
cells/cm2. The first change of the medium was 1 h after seeding, and unattached 
PMH were washed off with GIBCO HepatoZYME-SFM medium. 24 h after 
seeding, cells were washed two times with warm PBS and subsequently used for 
further experiments. 
 
3.5.6 Isolation of human hepatic stellate cells 
Human hepatic stellate cells (HSC) were isolated in co-operation with the Center 
for Liver Cell Research (Department of Surgery, University of Regensburg, 
Germany). After perfusion and separation of hepatocytes by an initial 
centrifugation step at 50 g (5 min, 4 °C) the super natant containing the non-
parenchymal cells were centrifuged at 700 g for 7 min (4 °C). The obtained cell 
pellet was resuspended in HSC medium and cells were seeded into T75 flasks. 
Within the first week, the medium was replaced daily, from the second week on 
medium change took place every 2-3 days. Under these conditions only HSC 
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proliferate. Liver sinusoidal endothelial cells (LSEC) die within the first 24 h. By 
cultivation on uncoated plastic HSC activate within the first 2 weeks and 
transdifferentiate to myofibroblast-like cells. Liver disease mediated HSC 
activation can be simulated in vitro that way. After 2 weeks the cell culture was 
split 1:3 by incubating the cells with Trypsin (0.05%)/EDTA (0.02%) solution. 
Thereby, only HSC detach, whereas Kupffer cells remain adherent to the plastic 
surface. Therefore, after the first passage only activated HSC remain in the cell 
culture which was confirmed by previously done analysis (Mühlbauer et al. 2006). 
 
3.5.7 Determination of cell number and viability 
Cell number and viability was determined by trypan blue exclusion test. The cell 
suspension was diluted 1:2 with trypan blue solution (Sigma, Deisenhofen, 
Germany) and applied on a Neubauer hemocytometer (Marienfeld GmbH, Lauda-
Königshofen, Germany). Cells with impaired cell membrane integrity are stained 
blue, and therefore, can be clearly distinguished from intact cells which appear 
white under microscopic inspection. The cell number could be calculated after 
counting cells in all four quadrants of the hemocytometer, each containing sixteen 
smaller squares, with the following equation: 
 
Cell number/ml = Z x DF x 104 ÷ 4 
 Z = counted cell number in all four quadrants 
 DF = dilution factor (in the described procedure the factor is 2) 
 
The ratio of viable cells could be determined by setting the number of unstained 
cells in relation to the total cell number (blue und unstained cells). 
 
3.5.8 Freezing cells for storage 
To freeze cells for storage, cells were trypsinized, centrifuged and resuspended in 
5 ml DMEM. Cells were counted, and 1 x 106 cells were pipetted in cryotube vials 
(Nunc, Roskilde, Denmark) and centrifuged again. The supernatant was 
discarded, and the obtained cell pellet was resuspended in 1 ml of freezing 
medium. To gently freeze the cell suspension the temperature was lowered 
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stepwise using a Nicool LM 10 freezing machine (Air Liquide, Düsseldorf, 
Germany) following the listed program: 
 
Level 4:  30 min  
Level 8:  30 min  
Level 10:  30 min  
 
Thereafter, the cryotube vials containing the frozen cell suspension were 
transferred to a liquid nitrogen storage tank. 
 
Thawing of the frozen cell stocks was done quickly with a water bath adjusted to 
37 °C. The defrosted cell suspension was transferre d into 8 ml of warm DMEM 
and centrifuged at 300 g for 5 minutes. The obtained cell pellet was resuspended 
in 10 ml of warm DMEM and pipetted into a T25 cell culture flask. 
 
3.6 Isolation and analysis of RNA 
3.6.1 RNA isolation and determination of RNA concentration 
RNA isolation was performed with the RNeasy® mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The principle of RNA 
isolation is based on the adsorption of RNA to hydrophilic silicon-gel membranes 
in presence of suitable buffer systems. Biological samples were first lysed and 
homogenized in the presence of a highly denaturing guanidine isothiocyanate 
containing buffer, which immediately inactivates RNases to ensure isolation of 
intact RNA. To homogenize tissue samples a hand-held rotor-stator homogenizer 
(Xenox Motorhandstück 2.35 with a Roti®-Speed-Rührer Ø 7 mm, Carl Roth, 
Karlsruhe, Germany) has been used. After lysis, ethanol has been added to 
provide ideal conditions for the binding of RNA to the silica-gel membranes. 
Contaminants have been washed away with suitable buffers before RNA was 
eluted in water and stored at -80 °C. The concentra tion of RNA was measured 
with the NanoDrop® ND-1000 UV/VIS spectrophotometer (Peqlab, Erlangen, 
Germany). 
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3.6.2 Reverse transcription of RNA to cDNA 
Transcription of RNA to complementary DNA (cDNA) was conducted with the 
Reverse Transcription System Kit (Promega, Mannheim, Germany) which uses 
avian myeloblastosis virus reverse transcriptase (AMV RT). The working solution 
was pipetted with contamination-free aerosol filter pipet tips after the following 
pipetting scheme: 
 
0.5 µg  RNA 
5 µl   MgCl2 (25 mM) 
2.5 µl  10x reverse transcription buffer 
2.5 µl   dNTP mix (10 mM) 
1.25 µl  random primer 
0.625 µl  RNasin ribonuclease inhibitor 
ad 25 µl  H2Odest. 
 
For reverse transcription the samples have been incubated in a GeneAmp® PCR 
cycler (Applied Biosystems, Foster City, USA) for 30 min at 42 °C. For 
denaturation of the AMV RT the temperature has been raised to 99 °C for 5 min. 
After cooling down to 4 °C the obtained cDNA was di luted with 75 µl H2Odest. and 
used immediately or stored at -20 °C. 
 
3.6.3 Quantitative real time polymerase chain reaction 
To quantify the expression of specific mRNA, quantitative real time polymerase 
chain reaction (qRT-PCR) has been performed with the LightCycler II system 
(Roche Diagnostics, Mannheim, Germany). The qRT-PCR is principally based on 
a conventional polymerase chain reaction (PCR), but offers the additional 
possibility of quantification, which is accomplished by fluorescence measurements 
at the end and/or during a PCR cycle. As fluorescent reagent SYBR® Green 
(QuantiTect SYBR® Green PCR Kit, Qiagen, Hilden, Germany) has been used. 
SYBR® Green intercalates with double-strand DNA whereby the fluorescence 
emission rises significantly. Therefore, the fluorescence signal increases 
proportionally with the amount of PCR products. To quantify the expression of a 
specific gene of interest, the results have been normalized to the housekeeper 
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gene β-actin for human samples and to 18s rRNA for murine samples, 
respectively. The results were evaluated with the LightCycler software version 3.5 
(Roche Diagnostics, Mannheim, Germany) following the manufacturer’s 
instructions. The qRT-PCR was performed according to the QuantiTect® SYBR® 
Green PCR Master Mix protocol (Qiagen, Hilden, Germany): 
 
10 µl   QuantiTect® SYBR® Green PCR Master Mix  
2 µl    cDNA 
0.5 µl   forward primer (20 µM)  
0.5 µl   reverse primer (20 µM)  
7 µl   H2Odest. 
 
Following standard scheme has been used and adapted to particular primer 
melting point temperature: 
 
Initial denaturation:   20 °C/s to 95 °C, 900 s  
Three step PCR:   20 °C/s to 95 °C, 15 s 
     20 °C/s to 55-65 °C, 20 s, 40 cycles 
     20 °C/s to 72 °C, 20 s 
Analysis of melting curve:  20 °C/s to 95 °C, 0 s 
     20 °C/s to 65 °C, 15 s 
     0.1 °C/s to 95 °C, 0 s 
     20 °C/s to 40 °C, 30 s 
 
For validation, after qRT-PCR 5-10 µl of the PCR product has been mixed with 
loading buffer (Peqlab, Erlangen, Germany) and loaded on a agarose gel with 
ethidium bromide (50 µg/100 ml gel) to determine the PCR product length. Each 
experimental condition was performed in triplicates and experiments were 
repeated at least three times. 
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Table 3.1 Used forward and reverse primers for qRT-PCR, Species: mouse or human. 
 
name forward primer reverse primer 
human α-sma 5’-CGT GGC TAT TCC TTC GTT AC 5’-TGC CAG CAG ACT CCA TCC 
human β-actin 5’-CTA CGT CGC CCT GGA CTT CGA GC 5’-GAT GGA GCC GCC GAT CCA CAC GG 
human collagen I 5’-CGG CTC CTG CTC CTC TT 5’-GGG GCA GTT CTT GGT CTC 
human IL8 5’-TCT GCA GCT CTG TGT GAA GGT GCA GTT 5’-AAC CCT CTG CAC CCA GTT TTC CT 
human MCP-1 5’-CGC GAG CTA TAG AAG AAT CAC 5’-TTG GGT TGT GGA GTG AGT GT 
murine 18s 5’-AAA CGG CTA CCA CAT CCA AG 5’-CCT CCA ATG GAT CCT CGT TA 
murine collagen I 5’-CGG GCA GGA CTT GGG TA 5’-CGG AAT CTG AAT GGT CTG ACT 
murine CYP2E1 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
murine ICAM-1 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
murine IL-1α QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
murine MCP-1 5’-TGG GCC TGC TGT TCA CA 5’-TCC GAT CCA GGT TTT TAA TGT A 
murine p47phox QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
murine TGF-β QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
murine TIMP-1 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
murine TNF QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
 
Primers were synthesized by SIGMA Genosys (Hamburg, Germany) or purchased 
as QantiTect Primer Assays form Qiagen (Hilden, Germany). The lyophilized 
primers were solved in H2Odest. (SIGMA Genosys primers) or TE buffer (QantiTect 
Primer Assays), respectively, and stored at -20 °C.  
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3.7 Protein analysis 
3.7.1 Preparation of whole cell protein extracts 
Used buffer: 
RIPA buffer 50 mM  Tris/HCl; pH 7.5 
150 mM  NaCl 
1% (v/v) Nonidet® P40 
0.5% (w/v) Sodium desoxycholate 
0.1% (w/v) SDS  
 
To extract whole cell protein from cell lines the cell culture medium was discarded 
and cells were washed once with PBS, then scraped off with a cell scraper 
(Corning, NewYork, USA) and taken up into 1 ml of cooled PBS. After 
centrifugation (1700 g, 5 min, 4 °C) the cell pelle t was resuspended in 200 µl RIPA 
buffer and treated with an ultrasonoscope (Sonoplus hp 70, Bandelin electronics, 
Berlin, Germany) 10 x 3 s at an intensity of 40% for cell lysis. Subsequently, the 
solved proteins were separated from the non soluble cell components by 
centrifugation at 20,000 g (10 min, 4 °C). The prot ein solution was transferred into 
new reaction tubes and stored at -20 °C. 
 
3.7.2 Preparation of nuclear protein extracts 
Used buffers: 
Buffer 1 (hypotonic buffer) 10 mM  Hepes; pH 7.9 
10 mM  KCl 
0.1 mM EDTA 
0.1 mM  EGTA 
 
Buffer 2 (lysis buffer) 20 mM  Hepes; pH 7.9 
0.4 mM  NaCl 
1 mM  EDTA 
1 mM   EGTA 
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Before use, the buffers were supplemented with 1 mM DTT and cooled on ice. 
Cells were detached from cell culture plates by trypsination and centrifuged at 
700 g for 5 min (4 °C). Subsequently, the cell pell et was resuspended in 400 µl of 
buffer 1 (hypotonic buffer) and incubated for 15 min on ice, resulting in cell 
swelling. This leads to fragile cell membranes. Addition of 25 µl of the detergent 
Nonidet-P40 (Roche Diagnostics, Mannheim, Germany) causes leakage of the 
cytoplasmatic protein into the supernatant. After centrifugation at 10,000 g for 
5 min (4 °C) the supernatant with the cytoplasmatic  fraction has been discarded 
and the pelleted nuclei were resuspended in 50 µl of buffer 2 (lysis buffer) and 
incubated for 15 min (on ice) on a orbital shaker for lysis. Remaining cell debris 
were removed by centrifugation (16,000 g, 10 min, 4 °C) and the supernatant, 
containing the solved nuclear proteins, was used immediatedly for further analysis 
or shock frosted in liquid nitrogen and stored at -80 °C. 
 
3.7.3 Determination of protein concentration 
To determine the protein concentrations of protein solutions the BCA Protein 
Assay Kit (Pierce, Rockford, USA) was used. The assay combines the reduction of 
Cu2+ to Cu1+ by protein in an alkaline medium with the highly sensitive and 
selective colorimetric detection of the cuprous cation Cu1+ by bicinchoninic acid 
(BCA). The first step is the chelation of copper with protein in an alkaline 
environment to form a blue-colored complex. In this reaction, known as the biuret 
reaction, peptides containing three or more amino acid residues form a colored 
chelate complex with cupric ions in an alkaline environment. One cupric ion forms 
a colored coordination complex with four to six nearby peptides bonds. In the 
second step of the color development reaction, BCA, a highly sensitive and 
selective colorimetric detection reagent reacts with the cuprous cation Cu1+ that 
was formed in step 1. The purple-colored reaction product is formed by the 
chelation of two molecules of BCA with one cuprous ion. The BCA/copper complex 
is water-soluble and exhibits a strong linear absorbance at 562 nm with increasing 
protein concentrations. 200 µl of alkaline BCA/copper(II) solution (50 parts of 
solution A mixed with 1 part of solution B) was added to 2 µl of protein solution 
using a 96-well plate and have been incubated for 1 h at RT. Thereafter the purple 
color was measured at 562 nm with a spectrophotometer (EMax® Microplate 
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Reader, MWG Biotech, Ebersberg, Germany). The optical absorbance values 
could be translated into specific protein concentrations by parallel quantification of 
a BSA standard. 
 
3.7.4 SDS polyacrylamid gel electrophoresis 
Used buffers: 
Laemmli buffer 62.5 mM Tris/HCl; pH 6.8 
2% (w/v) SDS 
10% (v/v) Glycerine 
5% (v/v) β-Mercaptoethanol 
 
Running buffer 25 mM Tris/HCl; pH 8.5 
200 mM Glycine 
0.1% (w/v) SDS 
 
10% Resolving gel 7.9 ml  H2Odest. 
5.0 ml  1.5 M Tris/HCl; pH 8.8 
0.2 ml  10% (w/v) SDS 
6.7 ml  Acrylamide/Bisacrylamide 
  30%/0.8% (w/v) 
0.2 ml  Ammonium persulfate 
  10% (w/v) 
0.008 ml TEMED 
 
5% Stacking gel 2.7 ml  H2Odest. 
0.5 ml  1.0 M Tris/HCl; pH 6.8 
0.04 ml 10% (w/v) SDS 
0.67 ml Acrylamide/Bisacrylamide 
  (30%/0.8% w/v)  
0.04 ml Ammonium persulfate 
  10% (w/v) 
0.004 ml TEMED 
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The protein solutions were heated at 95 °C for 5 mi n in Laemmli buffer and applied 
on a SDS polyacrylamid gel for protein fractionation by size at 35 mA/150 V (XCell 
SureLock™ Mini-Cell, Invitrogen, Karlsruhe, Germany). As size marker the Full 
Range Rainbow Molecular Weight Marker (GE Healthcare, Freiburg, Germany) 
was used. 
 
3.7.5 Western blotting 
Used buffer: 
Transfer buffer 10% (v/v)  Methanol 
25 mM  Tris 
190 mM  Glycine 
 
To detect the proteins after SDS-PAGE by use of specific antibodies the proteins 
were transferred electrophoretically to a nitrocellulose membrane (Invitrogen, 
Karlsruhe, Germany) at 220 mA/300 V for 1.5 h (XCell II Blot Module, Invitrogen, 
Karlsruhe, Germany). To block unspecific binding sites, the membrane was bathed 
in PBS containing 3% BSA or 5% milk powder for 1 h at RT. Then, the membrane 
was incubated with a specific primary antibody (Table 3.2) over night at 4 °C. After 
washing, the membrane was incubated with a secondary horseradish peroxidase 
(HRP) conjugated antibody (Table 3.2) for 1 h at RT. Thereafter, the membrane 
was washed with PBS and incubated with the ECL Plus Western Blotting 
Detection System (GE Healthcare, Freiburg, Germany) for 1 min. This system 
utilizes chemiluminescence technology for the detection of proteins. It consists of 
the acridan substrate Lumigen PS-3, which is converted to an acridinium ester 
intermediate when catalyzed by HRP. The ester intermediate reacts with peroxide 
in alkaline conditions and emits light, which was detected by autoradiography 
using a Biomax film (Kodak, Stuttgart, Germany) and a Curix 60 automatic film 
developer (Agfa, Cologne, Germany). All incubation steps were done on a KS 260 
Basic Orbital Shaker (IKA®; Staufen, Germany). Western blot experiments were 
repeated at least three times. 
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Table 3.2 Used primary and secondary antibodies for western blot analysis; used dilution; 
manufacturing company. Secondary antibodies are conjugated with horseradish peroxidase (HRP) 
 
Primary Antibody Diluton Manufactoring company 
Actin (mouse) 1:20,000 Sigma, Deisenhofen 
IκB-α (mouse) 1:1,000 Santa Cruz, Heidelberg 
Secondary Antibody Dilution Manufactoring company 
anti-mouse HRP 1:3,000 Santa Cruz, Heidelberg 
 
3.7.6 Quantification of NFκB activity 
To quantify NFκB activity in nuclear extracts, the TransAM NFκB p65 Transcription 
Factor Assay Kit (Active Motif, Rixensart, Belgium) has been used. Analysis was 
performed according to manufacturer’s instructions. The kit contains a 96-well 
plate on which an oligonucleotide containing the NFκB consensus site (5’-
GGGACTTTCC-3’) has been immobilized. The active form of NFκB specifically 
binds to this oligonucleotide. The primary p65 antibody used to detect NFκB 
recognize an epitope on the p65 NFκB subunit that is accessible only when NFκB 
is activated (i.e. after IκBα degradation; see chapter 2.4.1). Quantification was 
done by spectrophotometry after incubation with a HRP-conjugated secondary 
antibody. Each experimental condition was performed in triplicates and 
experiments were repeated at least twice. 
 
3.7.7 Quantification of caspase-3/7 activity 
Caspases, or cysteine-aspartic acid proteases, are a family of cysteine proteases, 
which play essential roles in apoptosis. There are two types of apoptotic caspases: 
initiator (apical) caspases and effector (executioner) caspases. Initiator caspases 
(e.g. caspase-2, -8, -9 and -10) cleave inactive pro-forms of effector caspases, 
thereby activating them. Effector caspases (e.g. caspase-3, -6 and -7) in turn 
cleave other protein substrates within the cell, to trigger the apoptotic process. 
To analyze caspase-3/7 activity we used the Apo-One Homogeneous 
Caspase-3/7 Assay kit (Promega, Madison, WI, USA) according to the 
manufacturer's instructions. We used 6000 cells/well (96-well plate) and incubated 
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cells with the provided caspase substrate Z-DEVD-R110 for 1 h. Cleavage of the 
non-fluorescent caspase substrate Z-DEVD-R110 by caspase-3/7 liberates the 
fluorescent rhodamine 110, which was detected fluoro-spectrometrically with a 
SPECTRAFluor Plus microplate reader (Tecan, Männedorf, Switzerland) at 
wavelengths of 485 nm (excitation) and 520 nm (emission). Each experimental 
condition was performed in triplicates and experiments were repeated at least 
twice. 
 
3.7.8 Analysis of cell culture supernatants 
Analysis of cell culture supernatants were performed at the Department of Clinical 
Chemistry and Laboratory Medicine (University of Regensburg, Germany).  
Effects on cell viability were assessed by lactate dehydrogenase (LDH), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) leakage into the 
culture medium. Therefore, culture medium was centrifuged at 20,000 g for 5 min 
to pellet detached cells and cell debris. The clear supernatant was used for LDH, 
ALT and AST measurements. LDH was quantified indirectly by reduction of 
nicotinamide adenine dinucleotide (NAD+) to NADH by lactate dehydrogenase 
catalyzed oxidation of L-lactate to pyruvate. ALT and AST were quantified in a 
three-step-reaction, which results in a decrease of NADH concentration. Increase 
or decrease of NADH concentration could be detected spectrophotometryly by 
measurement of absorbance at 340 nm. Lactate dehydrogenase L-P (LDLP) kit, 
alanine aminotransferase (ALTP5P) kit and aspartate aminotransferase (ASTP5P) 
kit (all from Bayer HealthCare, Leverkusen, Germany) were used according to 
manufacturer’s instructions adapted to the Advia 1800 analyzer (Siemens 
Healthcare Diagnostics, Eschborn, Germany). Each experimental condition was 
performed (at least) in duplicates and experiments were repeated at least three 
times. 
 
3.8 Flow cytometry 
Suspensions of fluorescence labeled cells were analyzed by flow cytometry with a 
Coulter®EPICS®XL™ flow cytometer (Beckman Coulter, Krefeld, Germany) which 
uses an argon ion laser tuned to a wavelength of 488 nm. Cell types and their 
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physical and biochemical conditions can be characterized by detection of light 
scatter in forward and orthogonal directions together with the fluorescence signals. 
Measurements were evaluated with the Expo32 ADC Software version 1.1C 
(Beckman Coulter, Krefeld, Germany). Each experimental condition was 
performed in triplicates and experiments were repeated at least twice. 
 
3.8.1 Annexin V / Propidium iodide double staining 
In the early stages of apoptosis cells change the structure of their membrane, 
which leads to the exposure of phosphatidylserine on the membrane surface. In 
living cells, phosphatidylserine is transported to the inside of the lipid bilayer by the 
aminophospholipid translocase, a Mg2+ ATP dependent enzyme. At the onset of 
apoptosis, phosphatidylserine is translocated to the external membrane and 
serves as a recognition signal for phagocytes.  
Annexins are ubiquitous homologous proteins that bind phospholipids in the 
presence of calcium. Since the redistribution of phosphatidylserine from the 
internal to the external membrane surface represents an early indicator of 
apoptosis, Annexin V and its conjugates can be used for the detection of apoptosis 
because they interact strongly and specifically with exposed phosphatidylserine. 
The differentiation between apoptotic and necrotic cells can be performed by 
simultaneous staining with propidium iodide (PI), a dye that stains by intercalating 
into nucleic acid molecules. The cell membrane integrity excludes PI in viable 
cells, whereas necrotic cells are permeable to PI. Thus, dual parameter flow 
cytometric analysis allows for the discrimination between viable, early apoptotic 
and late apoptotic/necrotic cells. 
To quantify apoptotic cells we used the ApoTarget Annexin-V FITC Apoptosis Kit 
(Invitrogen, Karlsruhe, Germany). Therefore, we resuspended 2 x 105 cells in 
100 µl of the provided binding buffer and added 5 µl of the FITC-labeled Annexin V 
reagent and 10 µl of the PI solution. After incubation for 15 min at room 
temperature flow cytometric analysis was performed. The FITC-Annexin V signal 
was detected at a wavelength of 525 ± 12.5 nm, the PI signal at a wavelength of 
620 ± 12.5 nm. The result of the dual parameter flow cytometric analysis were 
depicted as dotplot and evaluated by quadrant analysis. The y-axis of the dotplot 
shows the PI fluorescent signal intensity, the x-axis the FITC-Annexin V 
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fluorescent signal intensity. The discrimination of viable, early apoptotic and late 
apoptotic/necrotic cells were done by means of different intensities of the FITC-
Annexin V or PI fluorescent signals. Viable cells show low FITC-Annexin V and PI 
fluorescence (lower left quadrant), early apoptotic cells show high FITC-Annexin V 
but low PI fluorescence (lower right quadrant) and late apoptotic/necrotic cells 
show both high FITC-Annexin V and PI fluorescence (upper right quadrant) (see 
Figure 3.3). 
 
 
Figure 3.3 Annexin V / Propidium iodide staining dot plot. 
 
To assess the effects of a specific apoptosis or necrosis inducing reagent the 
percental distribution of viable, early apoptotic and late apoptotic/necrotic cells 
related to the total of counted cell (104 cells) were calculated. 
 
3.8.2 Cell viability analysis via propidium iodide staining 
To differentiate between viable and non-viable cells only (disregarding early 
apoptotic cells), staining with PI alone is sufficient (see 3.8.1). Therefore, we 
resuspended 2 x 105 cells in 100 µl of PBS supplemented with 0.2% FCS and 
added 10 µl of PI solution. After incubation for 15 min at room temperature flow 
cytometric analysis was performed. Non-viable cells will be stained by PI and have 
been detected at a wavelength of 620 ± 12.5 nm. Resulting data (of 104 counted 
cells) were plotted on histograms as PI fluorescence intensity (x-axis) versus event 
counts (y-axis) as shown in Figure 3.4. 
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Figure 3.4 Histogram of flow cytometrical analysis 
of cell viability via propidium iodide staining. 
 
3.8.3 Flow cytometrical analysis of caspase-3 activity 
Caspase-3 activity (see also chapter 3.7.7) was quantified by flow cytometry using 
the CaspGLOW Fluorescein Active Caspase-3 Staining Kit (BioCat, Heidelberg, 
Germany) according to manufacturer’s instructions. Briefly, cells were washed two 
times with PBS, suspended in DMEM supplemented with 10% FCS and incubated 
with the FITC-conjugated caspase-3 inhibitor (FITC-DEVD-FMK) for 30 min at 
room temperature. Thereafter, cells were washed with the provided washing buffer 
and analyzed by flow cytometry. The FITC signal was detected at a wavelength of 
525 ± 12.5 nm. Percentages of FITC positive (active caspase-3) cells of 104 
analyzed cells were evaluated (see Figure 3.5).  
 
 
Figure 3.5 Histogram of flow cytometrical analysis 
of caspase-3 activity. 
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3.9 Functional assays 
3.9.1 XTT-proliferation assay 
Cell proliferation was quantified with the XTT kit (Roche Diagnostics, Mannheim, 
Germany). The assay is based on the ability of metabolic active cells to reduce the 
tetrazolium salt XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[phenylamino)carbonyl]-2H-tetrazolium hydroxide) to orange colored compounds 
of formazan. The dye formed is water soluble and dye intensity can be read with a 
spectrophotometer at a wavelength of 450 nm and a reference absorbance 
wavelength of 650 nm. The intensity of the dye is proportional to the number of 
metabolic active cells.  
To quantify the effects of certain reagents on cell proliferation, cells were seeded 
in 96-well tissue culture plates (4000 cells per well) and incubated for 4 h in 
medium containing 10% FCS. Thereafter, medium was taken off and cells were 
starved for 16 hours in FCS free medium. After a further medium change and 
addition of specific stimulatory reagents, cells were incubated for different time 
intervals (1-7 days). At the chosen time points XTT reagent was added and the 
intensity of the forming dye was measured two hours thereafter with an EMax 
Microplate Reader (MWG Biotech, Ebersberg, Germany). Values of optical density 
(OD) at individual time points were corrected for background by subtracting the 
OD value of a blank well without cells. Each experimental condition was performed 
in triplicate and experiments were repeated three times. 
 
3.9.2 Migration assay 
The migratory potential of cells was quantified using the Cultrex 96 Well Cell 
Migration Assay (Trevigen, Gaithersburg, USA) according to the manufacturer’s 
instructions. This assay is based on two medium-filled compartments separated by 
a microporous membrane. In general, cells are placed in the upper compartment 
and are allowed to migrate through the pores of the membrane to the lower 
compartment, in which chemotactic agents are present. After an appropriate 
incubation time, migrated cells are detached from the lower side of the membrane 
by an appropriate detachment buffer and quantified using calcein 
acetoxymethylester (calcein AM). Calcein AM is internalized by the cells, and 
Materials and Methods  63 
intracellular esterases cleave the acetomethylester moiety to generate free 
calcein, which can be detected fluorometrically. 
Briefly, cells were seeded into the upper compartment of the provided 96-well 
plate (4 x 104 cells/well) in DMEM. The lower compartment was filled with DMEM 
supplemented with conditioned medium from fibroblasts and 10% FCS as 
chemoattractants. After incubation at 37°C for 5 h cell migration was quantified by 
fluorimetry using a SPECTRAFluor Plus microplate reader (Tecan, Männedorf, 
Switzerland). Each experimental condition was performed in triplicate and 
experiments were repeated twice. 
 
3.10 Animal experiments 
3.10.1 Animal treatment and sample asservation 
Female BALB/c mice were purchased from Charles River Laboratories (Sulzfeld, 
Germany) at 6 weeks of age and housed in a 22°C con trolled room under a 12 h 
light-dark cycle with free access to food and water. After 1 week of acclimatization 
mice were divided into experimental groups (5-6 mice) and fed with standard chow 
(Ssniff® R/M-H Cat.# V1534-0) as control diet or with experimental chows as 
indicated. All chows were prepared by Ssniff (Soest, Germany).  
At the end of the experiments, mice were sacrificed by heart puncture under 
ketamine/xylazine anesthesia according to the guidelines of the Central Animal 
Facility (ZTL) of the University of Regensburg (Regensburg) (Central Animal 
Facility (ZTL) of the University of Regensburg 2009). Ketamine and xylazine was 
purchased from the Central Animal Facility (ZTL) of the University of Regensburg. 
Tissue sections for gene expression or glycogen analysis were frozen in liquid 
nitrogen immediately after organ explantation and stored at -80 °C, whereas tissue 
for histological analysis was fixed for 24 hours in buffered formaldehyde solution 
(3.7% in PBS) at room temperature, dehydrated by graded ethanol and embedded 
in paraffin. For serum analysis murine blood was collected by heart puncture 
under deep anesthesia. After clotting (30 min on ice) blood was centrifuged at 
2000 g to remove cellular components. Serum (supernatant) was used 
immediately for further analysis or stored at -80 °C. 
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3.10.2 Murine NASH model 
Mice were divided into 3 groups (5-6 mice per group) and fed either with control 
diet or the NASH inducing Paigen-diet (see also chapter 2.7.5.5.5) with or without 
supplementation with 1.37% (w/w) XN rich hop extract, resulting in a final XN 
content of 1% (w/w), for 3 weeks. The XN rich hop extract that contains XN at 73% 
(w/w) was provided by Nateco (Wolnzach, Germany). The Paigen-diet was 
prepared according to Matsuzawa et al. and consisted of standard chow enriched 
with 15% fat (cocoa butter), cholesterol (1.25%) and sodium cholate (0.5%) 
(Matsuzawa et al. 2007).  
 
3.10.3 Toxicity study 
Mice were divided into 2 groups (6 mice per group) and fed either with control 
(standard) diet or standard diet supplemented with 0.5% (w/w) XN for 3 weeks. XN 
was obtained from Alexis Biochemicals (Lausen, Switzerland) with a purity ≥ 98% 
as determined by HPLC.  
 
3.11 Histology and Immunohistochemistry 
For histological and immunohistochemical analysis tissue was fixed for 24 hours in 
buffered formaldehyde solution (3.7% in PBS) at room temperature, dehydrated by 
graded ethanol and embedded in paraffin. Sections were cut at 5 µm and stuck on 
glass slides (Menzel-Gläser, Braunschweig, Germany) for further processing. 
 
3.11.1 Hematoxylin/Eosin staining 
Paraffin embedded tissue sections stuck on a glass slide were deparaffinized with 
xylene. Then, the tissue was rehydrated and dipped into an aqueous solution of 
hematoxylin. Hematoxylin binds to basophilic structures such as the anionic 
phosphate groups of nucleic acids. Following dehydration in alcohol, the tissue 
was dipped into an alcoholic solution of eosin. Eosin carries a negative charge and 
reacts with the cationic groups common to amino acids (eosinophilic structures). 
Once stained, the tissue was covered with a thin glass cover slip (Carl Roth, 
Karlsruhe, Germany) attached by mounting medium (Vector Laboratories, 
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Burlingame, USA). In general, the eosin imparts a pink to red color to proteins, and 
hematoxylin stains the basophilic structures, usually containing nucleic acids, such 
as ribosomes and the chromatin-rich cell nucleus, from blue to purple. Digital 
images were captured with an Olympus CKX41 microscope equipped with the 
ALTRA20 Soft Imaging System (Olympus, Hamburg, Germany). 
 
3.11.2 Immunohistochemical analysis of α-smooth muscle actin 
For visualization of α-sma positive cells the LSAB+ System-HRP Kit (Dako, 
Hamburg, Germany) was used according to the manufacturer’s instructions. The 
technique used in this kit is based on the LSAB (labeled streptavidin biotin) 
method. 
 
Used buffer: 
TBS-T buffer 6.1 g/l  Tris 
8.8 g/l  NaCl 
37 ml   1 N HCl 
ad 1 l  H2Odest.  pH 7.6 
0.05%  TWEEN 20 
 
First, paraffin embedded tissue sections stuck on a glass slide were deparaffinized 
with xylene. Then, endogenous peroxidase activity was quenched by incubating 
the tissue for 5 min in 3% H2O2. Subsequently, tissue was incubated with the 
primary antibody (monoclonal α-sma antibody (mouse) from Abcam, Cambridge, 
UK) for 30 min. For this purpose, the primary antibody was diluted 1:200 with 
TBS-T buffer. Thereafter, sequential incubations with the biotinylated link antibody 
(15 min) and peroxidase-labeled streptavidin (15 min) were performed. Staining is 
completed after incubation with the provided substrate-chromogen (3,3’-
diaminobenzidine) solution (15 min). For counterstaining the tissue was dipped 
into an aqueous solution of hematoxylin for 1 min. Finally, tissue was rinsed with 
H2Odest. and covered with a thin glass cover slip (Carl Roth, Karlsruhe, Germany) 
attached by mounting medium (Vector Laboratories, Burlingame, USA). Digital 
images were captured with an Olympus CKX41 microscope equipped with the 
ALTRA20 Soft Imaging System (Olympus, Hamburg, Germany). 
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3.12 Serology 
Analysis of serological parameters were performed at the Department of Clinical 
Chemistry and Laboratory Medicine (University of Regensburg, Germany) using 
appropriate kits, namely Albumin (ALB)-, Alkaline Phosphatase (ALPAMP)-, 
Alanine Aminotransferase (ALTP5P)-, Aspartate Aminotransferase (ASTP5P)-, 
Enzymatic Creatinine_2 (ECRE_2)-, Glucose Hexokinase II (GLUH)-, Lipase 
(LIP)-, Potassium (K)-, Sodium (Na)-, Total Protein II (TP)- and Urea Nitrogen 
(UN)-kit (all from Bayer HealthCare, Leverkusen, Germany) according to 
manufacturer’s instructions and adapted to the Advia 1800 analyzer (Siemens 
Healthcare Diagnostics, Eschborn, Germany). Murine serum samples were 
collected and prepared as described in chapter 3.10.1. Each experimental 
condition was performed (at least) in duplicates, experimental groups consisted of 
5-6 murine serum samples and experiments were repeated two times. 
 
3.13 Limulus Amebocyte Lysate assay  
For quantification of endotoxin serum levels, blood was collected and processed 
under sterile and pyrogen-free conditions and the obtained serum was stored in 
endotoxin free cups. Endotoxin concentration was determined using the Limulus 
Amebocyte Lysate (LAL) assay from Hycult Biotechnology (Uden, The 
Netherlands) according to the manufacturer’s instructions. Bacterial endotoxin, like 
lipopolysaccharide (LPS), is a fever-producing by-product of gram-negative 
bacteria commonly known as pyrogen. The principle of the used test is based on 
the fact that bacteria cause intravascular coagulation in the American horseshoe 
crab, Limulus polyphemus. The agent responsible for the clotting phenomena 
resides in the crab’s amebocytes. Bacterial endotoxin triggers an enzymatic 
reaction resulting in turbidity and gelation of the Limulus amebocyte lysate (LAL), 
which is utilized in this assay. Briefly, samples and standards were incubated with 
the provided LAL reagent. The enzymatic reaction, triggered by endotoxin, will 
cause a yellow color to develop upon cleavage of the chromophore, p-nitroaniline. 
The enzymatic reaction is then stopped by the addition of acetic acid. 
Subsequently, the absorbance at 405 nm was measured with an EMax Microplate 
Reader (MWG Biotech, Ebersberg, Germany). A standard curve was obtained by 
plotting the absorbance versus the corresponding concentrations of the E. coli 
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standards. Each experimental condition was performed in triplicates, experimental 
groups consisted of 5-6 murine serum samples and experiments were repeated 
two times. 
 
3.14 Glycogen assay 
Hepatic glycogen content was quantified using the Glycogen Assay Kit from 
BioVision (Heidelberg, Germany) according to the manufacturer’s instructions. 
Briefly, frozen liver tissue sections were weighed (approx. 50 mg) and 
homogenized in 1 ml H2Odest. under cooling. Thereafter, enzymes were inactivated 
by boiling the homogenates for 5 min. After cooling samples down to 37 °C, 
glycogen was hydrolyzed to glucose applying the provided hydrolyses enzyme 
mix. Thereafter, the provided OxiRed development enzyme mix was added and 
glucose was quantified colorimetrically using an EMax Microplate Reader (MWG 
Biotech, Ebersberg, Germany). Standard curve was assessed by dilution and 
quantification of the provided glycogen standard. Each experimental condition was 
performed in triplicates, experimental groups consisted of 5-6 murine blood 
samples and experiments were repeated three times. 
 
3.15 Cholesterol assay 
To quantify the hepatic total cholesterol content, total lipids/cholesterol were 
extracted from liver tissue sections using the method of Bligh and Dyer with slight 
modifications (BLIGH and DYER 1959). In brief, liver sections (approx. 50 mg) 
were weighed into 1 ml of a chloroform/methanol mix (2:1 v/v) and incubated for 
1 h at room temperature on an orbital shaker to extract the lipids. After addition of 
200 µl H2Odest., vortexing and centrifugation for 5 min at 3000 g, the lower lipid 
phase was collected and dried at room temperature. The lipid pellet was then re-
dissolved in 60 µl tert-butanol and 40 µl of a Triton X-114/methanol mix (2:1 v/v), 
and total cholesterol content was quantified using the Cholesterol/Cholesteryl 
Ester Quantitation Kit from BioVision (Heidelberg, Germany) according to the 
manufacturer’s instructions. The principle of this assay is based on enzymatic 
reactions which set free an easy detectable chromophore. First, cholesterol 
esterase hydrolyses esterified cholesterols into cholesterol. The free cholesterol is 
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then oxidized by cholesterol oxidase to yield H2O2, which interacts with a sensitive 
probe to produce resorufin. Quantification of resorufin was performed 
spectrophotometrically at 540 nm using an EMax Microplate Reader (MWG 
Biotech, Ebersberg, Germany). Each experimental condition was performed in 
triplicates, experimental groups consisted of 5-6 murine livers and experiments 
were repeated three times. 
 
3.16 Reagent preparation for in vitro experiments 
3.16.1 Palmitic acid preparation 
Palmitic acid (C16:0) is the most prevalent long-chain saturated free fatty acid 
found in circulation. In human blood it is bound to albumin, with a physiologic ratio 
of fatty acid to albumin of approximately 2:1. In states of insulin resistance and 
obesity (as major risk factors for NAFLD/NASH), serum fatty acid levels are 
commonly elevated, yielding ratios as high as 7.5:1 (Kleinfeld et al. 1996). In order 
to simulate hepatic steatosis, we recently established a palmitic acid-induced in 
vitro fatty liver model (Wobser et al. 2009). Palmitic acid was complexated to BSA 
in a molar ratio of approx. 6.7:1, thereby mimicking hyperlipidemic conditions.  
Preparation of the palmitic acid stock solution was carried out as described by 
Cousin et al. (Cousin et al. 2001). Briefly, a 100 mM palmitic acid stock solution 
was prepared in 0.1 mM NaOH by heating at 70 °C. A 10% (w/v) aqueous free 
fatty acid free BSA solution was prepared
.
 and maintained at 55 °C in a water 
bath. 10 mM palmitic acid/1% BSA solution was obtained by complexation of the 
appropriate amount of palmitic acid stock solution with 10% BSA at 55 °C for 
another 30 min. The obtained solution was then cooled to 25 °C, filter sterilized 
and stored at −20 °C until use. For in vitro experiments the 10 mM palmitic 
acid/10% BSA stock solution was heated for 15 min at 55 °C and subsequently 
cooled down to working temperature (37 °C) before u se. Samples indicated as 
controls received an appropriate amount of a vehicle control stock solution, which 
was prepared analogous to the palmitic acid/10% BSA stock solution, except for 
adding palmitic acid. 
 
Materials and Methods  69 
3.16.2 Xanthohumol preparation 
For in vitro experiments XN was dissolved in DMSO and added to cell culture at 
the indicated concentrations. Samples indicated as controls contained vehicle 
(DMSO) only. 
 
3.17 Statistical analysis 
Values are presented as mean ± SEM or mean ± SD as indicated. All experiments 
were repeated at least three times. Comparison between groups was made using 
the Student's unpaired t-test. Welch's correction was performed when required. A 
p-value < 0.05 was considered statistically significant. All calculations were 
performed using the statistical computer package GraphPad Prism version 4.00 
for Windows (GraphPad Software, San Diego, CA, USA). 
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4 Results 
 
As described in the introduction xanthohumol (XN) exhibits several biological 
effects (see chapter 2.4), however, with regards to effects on liver cells or liver 
diseases respectively, only few data are available (see also chapter 2.6).The aim 
of this thesis was to address this issue. 
 
In particular, the focus was placed on three aspects: 
4.1 Effects of xanthohumol on hepatic inflammation and fibrosis 
4.2 Effects of xanthohumol on hepatocellular carcinoma cells 
4.3 Safety profile of orally applied xanthohumol 
 
4.1 Effects of xanthohumol on hepatic inflammation 
and fibrosis 
4.1.1 Motivation 
Obesity and insulin resistance have reached epidemic proportions worldwide, and 
as one of the consequences non-alcoholic fatty liver disease (NAFLD) has 
emerged as a considerable public health concern. Previously, NAFLD was often 
considered a relatively benign condition, but today it is evident that a significant 
number of patients will progress to more severe stages of liver disease including 
NASH (non-alcoholic steatohepatitis). In addition to fatty infiltration of the liver, 
NASH is characterized by inflammation, hepatocellular damage and fibrosis (see 
also chapter 2.7.5.5) (Caldwell et al. 1999; Powell et al. 1990).  
The development of fibrosis, and particularly cirrhosis, is associated with a 
significant morbidity and mortality (see also chapters 2.7.2 and 2.7.3). Thus, there 
is a considerable imperative to develop antifibrotic strategies that are applicable to 
liver fibrosis. Such an approach is attractive since it is aimed at the final common 
pathological pathway of chronic liver disease, regardless of etiology.  
Here, we studied the effect of XN on primary human HSC and hepatocytes in vitro. 
Further, we tested the effects of XN on hepatic inflammation and fibrogenesis in a 
murine NASH model. 
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4.1.2 Effects of xanthohumol on HSC 
As mentioned in the introduction (see chapter 2.7.2) current evidence indicates 
that hepatic stellate cells (HSC) are central mediators of hepatic fibrosis in chronic 
liver disease including NASH. However, studies investigating the effects of XN on 
HSC were missing so far.  
 
4.1.2.1 Effects on HSC activation in vitro 
The activation of HSC is one of the central pathophysiological mechanism of liver 
fibrogenesis (Bataller and Brenner 2005; Friedman 2008). First, we therefore 
aimed to analyze the effect of XN on the in vitro activation process of HSC. Two 
days after isolation human HSC were exposed to XN at two different doses (5 µM 
and 10 µM) for three days. Here, and in subsequent experiments control cells 
were treated with DMSO at the same concentration as used as solvent for XN. 
Subsequently, mRNA expression of two established markers of HSC activation, 
namely collagen type I and alpha-smooth muscle actin (α-sma), was determined 
by qRT-PCR analysis. Treatment with XN significantly reduced the expression of 
collagen type I (collagen I) and α-sma compared to control HSC (Figure 4.1). 
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Figure 4.1 Two days after isolation HSC were incubated with xanthohumol (XN; 5 µM 
and 10 µM) for 72 h. Subsequently, α-sma and collagen I mRNA expression were 
analyzed by qRT-PCR analysis. *: p<0.05 compared to control. 
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4.1.2.2 Induction of apoptosis in activated HSC in vitro 
Once they are activated HSC are characterized by high resistance to apoptosis, a 
mechanism that has therefore been proposed to play a key role in the progression 
of fibrosis in chronic liver disease. Incubation of in vitro activated HSC with XN for 
6 h led to dose-dependent (0-20 µM) activation of caspase-3/7 (Figure 4.2).  
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Figure 4.2 In vitro activated HSC were incubated with different doses of XN. Caspase-3/7 
proteolytic activity was measured in cytosolic protein extracts by cleavage of the fluorigenic 
substrate Z-DEVD-rhodamine-110. Activities are represented as fold-increase of rhodamine-110 
fluorescence over control. *: p<0.05 compared to control. 
 
 
Incubation of HSC with higher doses of XN led to detachment of HSC. After 24 h 
incubation with 10 µM or 20 µM XN almost all cells appear positive for propidium 
iodide, indicating late apoptosis and necrosis (Figure 4.3). 
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Figure 4.3 Apoptosis was analyzed by flow cytometry applying annexin V and propidium iodide 
staining. Annexin V+ and PI- cells reflect early apoptosis while annexin V+ and PI+ cells indicate 
late apoptosis / secondary necrosis. 
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In line with these data, secretion of LDH is dose-dependently increasing in XN 
treated HSC after 24 h and is reaching a plateau at 20 µM (Figure 4.4). 
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Figure 4.4 24 h after XN stimulation vitality was measured as cell membrane lysis and release of 
lactate dehydrogenase (LDH) into supernatants. *: p<0.05 compared to control. 
 
4.1.2.3 Inhibition of NFκB activity and proinflammatory gene 
expression in HSC in vitro 
XN is known to inhibit NFκB activity in tumorous cells (Albini et al. 2006), and it 
has been shown that NFκB activity is crucial for both HSC activation and 
resistance to apoptosis (Elsharkawy et al. 2005; Hellerbrand et al. 1998a). Here, 
we found that XN stimulation reduces both basal as well as TNF induced NFκB 
activity in nuclear extracts of activated HSC (Figure 4.5).  
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Figure 4.5 NFκB activity in nuclear extracts of TNF and/or xanthohumol (XN) treated cells and 
control cells by ELISA. After 24 h serum depletion activated human HSC were stimulated with 
XN (5 µM) for 3 h, and subsequently, with TNF (10 ng/ml) for 2 h in serum free medium.  
*: p<0.05 
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Furthermore, XN inhibits TNF mediated IκB-α degradation in activated HSC 
(Figure 4.6).  
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Figure 4.6 Analysis of IκBα in protein extracts of TNF and/or xanthohumol (XN) treated cells and 
control cells by Western blotting. After 24 h serum depletion activated human HSC were 
stimulated with 5 µM or 10 µM xanthohumol (XN) for 3 h, and subsequently, with TNF (10 ng/ml) 
for 30 min in serum free medium. 
 
 
In accordance, XN inhibited TNF-induced MCP-1 expression, a proinflammatory 
chemokine that is de novo expressed during HSC activation and that is highly 
regulated via activation of the transcription factor NFκB in activated HSC 
(Hellerbrand et al. 1998b) (Figure 4.7). 
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Figure 4.7 MCP-1 mRNA expression in TNF and/or xanthohumol (XN) treated cells and control 
cells analyzed by qRT-PCR. After 6 h serum depletion activated human HSC were stimulated 
with XN (5 µM) and/or TNF (10 ng/ml) for 24 h in serum free medium. *: p<0.05 
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4.1.3 Effects of xanthohumol on primary human hepatocytes 
In vitro effects on HSC were achieved at the same or even lower concentrations 
as observed in human cancer cells of different origin (Colgate et al. 2007; Dell'Eva 
et al. 2007; Delmulle et al. 2006; Miranda et al. 1999). However, data regarding 
apoptotic or cytotoxic effects on primary human hepatocytes (PHH) were missing 
so far.  
 
Noteworthy, XN did not affect LDH or ALT (Figure 4.8) levels in the supernatant of 
PHH incubated with XN doses as high as 50 µM for 24 h.  
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Figure 4.8 Primary human hepatocytes (PHH) were incubated with xanthohumol (XN) for 24 h at 
the concentrations indicated. Viability was assessed as release of LDH and ALT into the 
supernatants. 
 
Flow cytometric analysis confirmed that there is no significant apoptosis or 
necrosis in PHH after 24 h stimulation with 25 µM or 50 µM XN (Figure 4.9).  
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Figure 4.9 Analysis of apoptosis by flow cytometric analysis using annexin V/PI staining. 
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However, at the same concentrations a significant inhibition of IL-8 expression was 
observed (Figure 4.10), another chemokine known to be regulated by NFκB.  
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Figure 4.10 Analysis of IL-8 mRNA expression by qRT-PCR in xanthohumol (XN; 20 µM) 
stimulated and control PHH. *: p<0.05 compared to control. 
 
 
Recent studies have shown that free fatty acids are capable of inducing NFκB and 
proinflammatory gene expression in hepatocytes (Joshi-Barve et al. 2007). Here, 
we confirmed significant induction of IL-8 expression in PHH following stimulation 
with 0.4 µM palmitic acid, and this induction was inhibited by simultaneous 
incubation with XN (Figure 4.11). 
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Figure 4.11 IL-8 mRNA expression in PHH stimulated with palmitic acid (PL; 0.4 µM) and/or 
xanthohumol (XN; 20 µM) for 24 h. PHH stimulated with the solvents DMSO and BSA served as 
control. *: p<0.05 
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4.1.4 In vivo effects of xanthohumol in a murine NASH model 
4.1.4.1 No affection of hepatic steatosis in the murine NASH model 
In vitro data indicate that XN exhibits antifibrogenic effects at concentrations that 
do not affect the viability of PHH but even suppress basal as well as free fatty acid 
induced expression of proinflammatory chemokines known to play a role in 
progression of NASH (Haukeland et al. 2006; Jarrar et al. 2008; Miranda et al. 
1999). These in vitro findings encouraged us to test the effect of XN in a dietary 
NASH model, named Paigen-diet (Nishina et al. 1993; Nishina et al. 1990), in mice 
(see also chapters 2.7.5.5.5 and 3.10.2). We selected this model since recently 
Matsuzawa et al. described that feeding this diet rich in fat (15%) and 
supplemented with cholesterol and cholate induced severe hepatic inflammation 
and fibrogenesis within 6 or 24 weeks, respectively (Matsuzawa et al. 2007). Here, 
we applied the Paigen-diet either alone or supplemented with 1.37% (w/w) XN rich 
hop extract, resulting in a final XN content of 1% (w/w), for 3 weeks. Mice 
receiving standard chow served as control. 
No significant differences were found between treatment groups regarding food 
and fluid intake or body weight throughout the study. However, liver body weight 
ratio was significantly lower in mice fed with Paigen+XN compared to mice 
receiving the pure Paigen-diet (Figure 4.12).  
 
liv
er
-
bo
dy
-
w
ei
gh
t-r
at
io
[%
]
0.0
2.5
5.0
7.5
10.0 **
Ctrl. Paigen Paigen
+XN 
12.5
liv
er
-
bo
dy
-
w
ei
gh
t-r
at
io
[%
]
 
Figure 4.12 Liver-body-weigh-ratios of mice fed the NASH inducing Paigen-diet either alone or 
supplemented with xanthohumol (Paigen+XN) for 3 weeks. Mice receiving standard chow served 
as control. *: p<0.05 
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Despite the short feeding period the Paigen-diet induced macroscopically visible 
hepatic steatosis that appeared similar in the Paigen+XN group (Figure 4.13).  
 
I II III
Ctrl. Paigen Paigen
+XN  
 
Figure 4.13 Representative macroscopic images of the livers of the three treatment groups. 
 
Histological analysis revealed microvesicular steatosis in both mice fed the 
Paigen-diet alone or in combination with XN (Figure 4.14).  
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Figure 4.14 HE-staining of liver tissue from mice fed Paigen (II, IV), Paigen+XN (III,VI) or control 
mice (I,IV). Representative images at 2 different magnifications (I-III:100X; IV-VI:200X) are shown. 
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It has been shown that cholesterol is the predominant lipid accumulating in the 
liver after Paigen-feeding. Also here, we found a significant increase of hepatic 
cholesterol levels after 3 weeks feeding this diet, and cholesterol levels did not 
differ between the Paigen and the Paigen+XN group, respectively (Figure 4.15). 
 
Ch
o
le
st
er
o
l
[n
m
o
l/m
g]
Ctrl. Paigen Paigen
+ XN  
0
50
100
150
200
* *
Ch
o
le
st
er
o
l
[n
m
o
l/m
g]
 
Figure 4.15 Intrahepatic cholesterol levels. *: p<0.05 compared to control. 
 
4.1.4.2 Inhibition of hepatic inflammation in a murine NASH model 
In addition to steatosis, histological analysis revealed significant inflammation and 
necrosis in mice fed with the Paigen-diet (Figure 4.14,II), but these 
histopathological changes were apparently less pronounced in the Paigen+XN 
group (Figure 4.14,III). In accordance, ALT and AST (Figure 4.16) serum levels 
were significantly increased in the Paigen-group but reduced to normal levels in 
mice fed Paigen+XN.  
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Figure 4.16 Analysis of ALT and AST serum levels. *: p<0.05 
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Further, both TNF and IL-1α expression were significantly increased in mice fed 
the Paigen-diet (Figure 4.17), but this increase was almost completely blunted in 
mice fed Paigen+XN.  
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Figure 4.17 Analysis of hepatic TNF and IL1-α mRNA levels by qRT-PCR. *: p<0.05 
 
 
Similarly, MCP-1 mRNA was significantly increased in mice fed the Paigen-diet 
compared to control fed mice, but the increase was diminished in the Paigen+XN 
group (Figure 4.18). 
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Figure 4.18 Analysis of hepatic MCP-1 mRNA levels by qRT-PCR. *: p<0.05 
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4.1.4.3 Inhibition of HCS activation and hepatic fibrosis in vivo 
Besides inflammatory gene expression, a significant increase of the mRNA levels 
of the profibrogenic genes TGF-β and TIMP-1 was observed in mice fed the 
Paigen-diet (Figure 4.19).  
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Figure 4.19 Analysis of hepatic TGF-β and TIMP-1 mRNA levels by qRT-PCR. *: p<0.05 
 
 
In contrast, hepatic mRNA levels of both profibrogenic genes in Paigen-XN mice 
did not differ significantly from control mice. After 3 weeks feeding the Paigen-diet 
we did not yet observe hepatic fibrosis in histological analysis. However, collagen 
type I mRNA was significantly increased in Paigen-diet but not in Paigen+XN fed 
mice compared to mice fed control diet (Figure 4.20). 
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Figure 4.20 Analysis of hepatic collagen I mRNA levels by qRT-PCR. *: p<0.05 
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In line with these observations, immunohistochemical staining of liver tissue from 
the Paigen group revealed α-sma positive cells along the sinusoids (Figure 4.21). 
In contrast, in livers from mice fed Paigen+XN or control diet no α-sma immuno-
signal was detected along the sinusoids indicating that the activation of HSC in 
response to the Paigen-diet was blunted by XN. 
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Figure 4.21 Immunohistochemical analysis of α-sma in liver tissue of mice fed Paigen (II), 
Paigen+XN (III) or control mice (I). α-sma positive HSC appear brownish. 
 
 
4.1.5 Summary 
Here, we could show that XN inhibits the activation of primary human HSC and 
induces apoptosis in activated HSC in vitro in a dose dependent manner 
(0-20 µM), but does not impair viability of primary human hepatocytes at even 
higher doses (50 µM). However, in both cell types XN inhibits NFκB activation and 
expression of NFκB dependent proinflammatory chemokines. In vivo, feeding of 
XN reduced levels of serum transaminases and hepatic expression of 
proinflammatory genes in a murine model of NASH. Moreover, XN treatment 
significantly inhibited hepatic expression of profibrogenic genes and activation of 
HSC in vivo. In conclusion, XN has the potential to ameliorate NASH induced liver 
injury, suggesting its potential use as functional nutrient to prevent progression of 
chronic liver disease. 
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4.2 Effects of xanthohumol on hepatocellular 
carcinoma cells 
4.2.1 Motivation 
Despite the extensive research on anticancer functions of XN, very few studies 
have evaluated the inhibitory effects of XN on hepatocellular carcinoma (HCC). 
More importantly, there exists no data concerning effects of XN on non-malignant 
primary human hepatocytes, which is a prerequisite for the use of XN as an 
anticancer agent. Here, we analyzed the effects of XN on two human HCC cell 
lines as well as on primary human hepatocytes (PHH). 
 
4.2.2 Induction of cell death in HCC cells but not in PHH 
First, we analyzed the effects of XN on the viability of the two human HCC cell 
lines HepG2 and Huh7. Microscopic observation revealed a marked decrease of 
the cell number after incubation with XN at a concentration of 25 µM for 24 h. 
Stimulation with higher XN concentrations led to an almost complete cell 
detachment (Figure 4.22).  
 
 
Figure 4.22 Representative phase-contrast images of HepG2 (upper row) and Huh7 (lower row) 
hepatocellular carcinoma cell line cultures after 24 h incubation with the indicated concentrations 
of xanthohumol (XN). 
 
Consistently, a significant increase of LDH and AST levels were detected in the 
supernatants of HCC cells after incubation with 10, 25, 50 and 100 µM XN (Figure 
4.23).  
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Figure 4.23 Hepatocellular carcinoma cells (Huh7) were incubated with xanthohumol (XN) for 24 h 
at the concentrations indicated. Viability was assessed as release of LDH and AST into the 
supernatants. *: p<0.05 compared to control. 
 
In contrast, but in line with the findings described in the previous chapter 4.1.3, 
primary human hepatocytes (PHH) appeared completely unaffected after 24 h 
incubation with XN concentrations as high as 100 µM (Figure 4.24).  
 
 
Figure 4.24 Representative phase-contrast images of primary human hepatocytes (PHH) after 
24 h incubation with the indicated concentrations of xanthohumol (XN). 
 
To further confirm this finding, PHH were detached by trypsination and stained 
with propidium iodide (PI), revealing no significant PI incorporation at any XN 
concentration up to 100 µM (Figure 4.25). 
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Figure 4.25 Flow cytometric analysis of propidium iodide (PI) stained PHH incubated with different 
XN concentrations for 24 h. 
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Further, no significant increase in LDH and AST levels were detected in the 
supernatants of PHH after incubation with XN at doses as high as 100 µM (Figure 
4.26; see also chapter 4.1.3). 
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Figure 4.26 Primary human hepatocytes (PHH) were incubated with xanthohumol (XN) at the 
indicated concentrations for 24 h. Viability was assessed as release of LDH and AST into the 
supernatants. PHH treated with 5% (v/v) ethanol for 24 h served as positive control (Pos.Ctrl. set 
to 100%). *: p<0.05 compared to control. 
 
 
4.2.3 Induction of apoptosis in HCC cells 
To further study the underlying mechanisms leading to HCC cell death upon 
stimulation with XN we measured the time-dependent activation of caspase-3/7 in 
HepG2 cells incubated with 25 µM XN within 24 h. After 12 h incubation 
caspase-3/7 activity was unaltered, but 6 hours later a significant increase was 
observed remaining on this elevated level for at least the next 6 h (24 h stimulation 
time) (Figure 4.27). A similar time course of caspase-3/7 activation was observed 
in Huh7 cells. 
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Figure 4.27 Caspase-3/7 activity in HepG2 cells stimulated with xanthohumol (XN) at a 
concentration of 25 µM for the time intervals indicated. *: p<0.05 compared to control. 
 
Next, the effect of different XN concentrations on caspase-3/7 activity in Huh7 and 
HepG2 cells were analyzed revealing a concentration dependent increase of 
caspase-3/7 activity in both cell lines, reaching a maximum at 50 µM XN (Figure 
4.28).  
 
Ctrl. 10 20 25 30 40 50 75 100
0
1
2
3
4
Ca
sp
as
e-
3/
7 
Ac
tiv
ity
[C
tr
l. 
se
t1
]
XN (µM)
*
*
*
*
*
Ca
sp
as
e-
3/
7 
Ac
tiv
ity
[C
tr
l. 
se
t1
]
 
Figure 4.28 Caspase-3/7 activity in Huh7 cells stimulated for 24 h with different XN 
concentrations as indicated. *: p<0.05 compared to control. 
 
At higher XN concentrations HCC cells detached, and accurate analysis of the 
caspase-3/7 was not possible with an ELISA based assay. To bypass this pitfall 
we additionally performed flow cytometric analysis, applying a FITC-labeled 
antibody against active caspase-3 (Figure 4.29). 
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Figure 4.29 Flow cytometric analysis of caspase-3 activity in Huh7 cells after incubation with 
different XN concentrations for 24 h. 
 
Here, basically all HCC cells revealed a positive signal for active caspase-3 after 
stimulation with 100 µM XN for 24 h (quantified in Figure 4.30). 
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Figure 4.30 Percentage of Huh7 cells with active caspase-3 after treatment with XN at indicated 
concentrations for 24 h determined by flow cytometry. *: p<0.05 compared to control. 
 
 
4.2.4 Inhibition of HCC cell proliferation and migration 
To further characterize the effect of XN on HCC cells, we performed the XTT 
assay (see also chapter 3.9.1) with both cell lines using different XN 
concentrations. Proliferation was significantly inhibited after incubation with 15 µM 
XN, whereas concentrations higher than 30 µM completely abrogated cell 
proliferation in HepG2 and Huh7 (Figure 4.31) cells. 
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Figure 4.31 Proliferation of HepG2 and Huh7 cells 72 h after stimulation with different 
concentrations of xanthohumol (XN) relative to control cells (set to 1).*:p<0.05 compared to 
control. 
 
Next, we analyzed whether XN affects the migration potential of HCC cells in vitro. 
For these experiments the Cultrex cell migration assay (see also chapter 3.9.2) 
was used and a short time span of 5 h was chosen to exclude pro-apoptotic or 
anti-proliferative effects of XN in the applied concentrations (10 µM or 25 µM). 
Noteworthy, we observed a significant inhibition of cell migration of HCC cells 
treated with 25 µM XN as compared to untreated control cells (Figure 4.32). 
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Figure 4.32 Quantification of migration of HepG2 and Huh7 cells incubated with XN (10 µM or 
25 µM) in comparison to untreated control cells (set to 1). *: p<0.05 compared to control. 
 
4.2.5 Inhibition of NFκB activation and IL-8 expression in HCC 
cells 
XN has been shown to affect NFκB activity, and we and others have shown that 
NFκB plays an important role in hepatocarcinogenesis (Amann et al. 2009; Arsura 
and Cavin 2005; Pikarsky et al. 2004). Thus, we further analyzed the effect of XN 
on NFκB activity in HCC cells. To avoid potential paracrine side effects of dead 
HCC cells on NFκB activity we chose a not toxic XN concentration of 2.5 µM and 
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stimulated the cells for only 3 h. In this case, XN exhibited no effects on basal 
NFκB activity in both cell lines. However, TNF (10 ng/ml) induced NFκB activity 
was significantly blunted in XN treated Huh7 cells even at this low concentration 
(Figure 4.33).  
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Figure 4.33 Basal and TNF induced (10 ng/ml; 15 min) NFκB activity in nuclear extracts of Huh7 
cells, which were preincubated with xanthohumol (XN; 2.5 µM; 3 h), compared to control cells.  
*: p<0.05 
 
Next, we analyzed the effect of XN on IL-8 expression in HCC cells, since IL-8 
expression is known to be regulated by NFκB in HCC cells (Iguchi et al. 2000; 
Joshi-Barve et al. 2007; Kubo et al. 2005), and previous studies indicate that IL-8 
is directly or indirectly involved in the progression of HCC (Kubo et al. 2005; Ren 
et al. 2003). In accordance with the effects on NFκB activity, basal IL-8 expression 
was not affected by stimulation with XN for 24 h, however, TNF induced IL-8 
expression was significantly lower in Huh7 cells pre-incubated with XN as 
compared to controls (Figure 4.34). 
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Figure 4.34 Analysis of basal and TNF (10 ng/ml for 1 h) induced IL-8 mRNA expression by 
qRT- PCR. *: p<0.05 
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4.2.6 Summary 
Here, we showed that xanthohumol induced apoptosis at a concentration of 25 µM 
in two HCC cell lines (HepG2 and Huh7). Furthermore, xanthohumol repressed 
proliferation and migration, as well as TNF induced NFκB activity and interleukin-8 
expression in both cell lines at even lower concentrations. In contrast, 
xanthohumol concentrations up to 100 µM did not affect viability of primary human 
hepatocytes in vitro, in accordance with the findings observed in chapter 4.1.  
In summary, our data showed that xanthohumol can ameliorate different pro-
tumorigenic mechanisms known to promote HCC progression, indicating its 
potential as promising therapeutic agent that selectively affects cancer cells. 
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4.3 Safety profile of orally applied xanthohumol 
4.3.1 Motivation 
So far, two long term safety studies of XN have been reported. Vanhoecke et al. 
applied a daily dose of approximately 35 mg XN/kg b.w. per day to mice for four 
weeks, and did not observe any noticeable signs of toxicity (Vanhoecke et al. 
2005b). Particularly, there were no signs of hepatotoxicity and differences 
regarding lipid or carbohydrate metabolism. In a second study, Hussong at al. 
applied 1000 mg XN/kg b.w. per day by gavage to female Sprague Dawley rats for 
four weeks (Hussong et al. 2005). Also in this carefully performed study no 
remarkable treatment-related changes were observed in most organs, and 
importantly, there were no adverse effects on female reproduction or the 
development of offspring. However, in XN treated rats liver weight was reduced 
and histological investigation indicated a loss of hepatic glycogen, suggestive of 
mild hepatoxicity. Particularly with respect to long term application even weak 
hepatoxicity is a critical issue since it harbors the risk to progress to chronic 
hepatic inflammation and fibrosis (Ramachandran and Kakar 2009; Stravitz and 
Sanyal 2003). 
However, total liver weight and glycogen content are only unspecific and vague 
signs of hepatotoxicity. Furthermore, based on the studies of Hussong et al. 
(Hussong et al. 2005) and Vanhoecke et al. (Vanhoecke et al. 2005b) it is not clear 
whether the different XN doses or species differences account for the differing 
results regarding potential hepatoxicity. 
Thus, in the present study, we aimed to detect possible side effects of high dose 
XN (1000 mg/kg b.w. per day) chronically fed to mice with an emphasis on 
affection of liver function and homeostasis.  
 
4.3.2 In-life parameters  
To study potential toxic effects of orally applied xanthohumol (XN) in vivo, we fed 
mice with standard chow supplemented with 0.5% (m/m) XN for 3 weeks to 
achieve a daily dose of approximately 1000 mg/kg b.w. per day. Control mice 
received the same chow without XN supplementation. Monitoring of daily food 
intake (Figure 4.35, 3.2 ± 0.20g XN supplemented chow per mouse and day) 
Results  92 
confirmed that we achieved this goal (average XN dose 998 ± 21 mg XN/kg b.w. 
per day), and daily food and herewith XN consumption, respectively, did not 
significantly change over time. Furthermore, food and water (Figure 4.35) intake 
as well as total body weight gain (Figure 4.36) did not significantly differ between 
XN fed and control mice.  
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Figure 4.35 Analysis of in-life parameters during oral xanthohumol feeding. Mean daily food and 
water intake (per mouse) of xanthohumol treated (XN) and control (Ctrl.) mice. 
 
Final body weights were 16.1 ± 0.7 g for control mice and 16.1 ± 1.1 g for XN fed 
mice.  
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Figure 4.36 Mean total body weight during the experimental period (3 weeks) of xanthohumol 
treated (XN) and control (Ctrl.) mice. 
 
Fecal excrements appeared normal in quantity, shape and consistency, solely 
color was more yellowish due to excreted XN. Throughout the experimental period 
no obvious clinical symptoms or deaths were observed. 
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4.3.3 Effects on function and homeostasis of inner organs 
Mice were sacrificed after 3 weeks of feeding and investigated for anomalies. 
Blood was collected and inner organs were explanted for further investigation. 
Relative size of lung, heart, thymus, spleen, and kidney was not affected by XN, 
and neither macroscopical nor microscopical analysis revealed abnormalities or 
signs of toxicity caused by XN feeding (Figure 4.37). 
 
 
Figure 4.37 Representative photographs of lung, heart, thymus, spleen, kidney (from left to right) 
and corresponding histological pictures of sections of the according organs of xanthohumol 
treated (XN) and control (Ctrl.) mice (H&E Staining; bars indicate 500 µm and 100 µm in the 
insert, respectively). 
 
Further, also the colon appeared normal (Figure 4.38), and colon length did not 
differ between groups (control: 9.3 ± 0.87 cm vs. XN: 8.53 ± 0.52 cm; p = 0.094).  
 
Figure 4.38 Macroscopical and histological pictures of the colon of xanthohumol treated (XN) and 
control (Ctrl.) mice (H&E Staining; bars represent 100 µm). 
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To further detect potential intestinal toxicity of XN we measured bacterial 
endotoxin concentration in the serum as a marker for gut barrier dysfunction. 
Endotoxin levels in both groups were low and did not differ significantly between 
XN treated and control mice (Figure 4.39).  
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Figure 4.39 Endotoxin serum levels of xanthohumol treated (XN) and control (Ctrl.) mice 
assessed by limulus amebocyte lysate assay. 
 
Due to the difficult explantation and histological processing of the pancreas, we 
decided to assess lipase activity in the serum as a marker for potential toxicity in 
the exocrine pancreas. Also here, no significant differences were found between 
groups (Table 4.1). Further, blood creatinine and urea nitrogen serum 
concentrations indicated an intact kidney function in both groups. Sodium and 
potassium as well as total protein concentrations in the serum were found to be 
unaffected by XN treatment as well (Table 4.1).  
 
Table 4.1: Serum analysis of control and xanthohumol (XN) treated mice (mean ± stdv). 
 
Parameter  control  XN p-value 
creatinine (mg/dL)  0.24 ± 0.04  0.26 ± 0.05 0.532 
lipase (U/l)  44 ± 11  41 ± 14 0.732 
potassium (mmol/l)  6.8 ± 2.0  5.6 ± 0.9 0.300 
sodium (mmol/l)  154.4 ± 5.4  154 ± 5.2 0.913 
total protein (g/l)  46.8 ± 4.1  43.5 ± 2.1 0.189 
urea nitrogen (mg/dl)  26.5 ± 6.7  26.1 ± 5.5 0.931 
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4.3.4 Effects on liver function and homeostasis 
Next to the gut the liver is generally exposed to highest doses of food derived 
compounds due to the direct blood transport from the gut via the portal vein. 
Furthermore, in vitro studies using liver microsomes indicate that the liver is a 
major site of XN biotransformation (Nikolic et al. 2005; Yilmazer et al. 2001a; 
Yilmazer et al. 2001b). Thus, we put emphasis on the identification of potential 
side effects of oral XN administration on the liver.  
After 3 weeks neither absolute liver weight nor liver to body weight ratio differed 
significantly between XN treated and control mice (Figure 4.40).  
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Figure 4.40 Absolute liver weight and liver-body-weight-ratio of xanthohumol treated (XN) and 
control (Ctrl.) mice after 3 weeks. 
 
In line with these findings, macroscopical examination of the livers revealed no 
signs of hepatotoxicity (Figure 4.41).  
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Figure 4.41 Representative photographs of the whole liver of xanthohumol treated (XN) and 
control (Ctrl.) mice. 
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Furthermore, no pathological changes were observed in histological investigation 
(Figure 4.42). 
 
 
Figure 4.42 Histological analysis of hepatic tissue sections (H&E staining; bars represent 
500 µm in the upper and 100 µm in the lower row) of xanthohumol treated (XN) and control (Ctrl.) 
mice. 
 
Next, we performed biochemical analysis of serum parameters indicative of liver 
damage and hepatic synthesis capacity. Alanine and aspartate aminotransferase 
(ALT, AST) as well as albumin serum levels were similar in XN treated and control 
mice (Table 4.2).  
 
Table 4.2: Liver relevant serum biochemistry of control and XN treated mice (mean ± stdv). 
 
Parameter  control  XN p-value 
ALT (U/l)  43.2 ± 12.1  41.1 ± 11.5 0.790 
AST (U/l)  222 ± 116  177 ± 62 0.507 
albumin (g/l)  30.6 ± 2.9  27.5 ± 1.7 0.102 
glucose (mg/dL)  230 ± 66  255 ± 50 0.613 
 
 
Also glucose serum levels (Table 4.2) as well as hepatic glycogen content (Figure 
4.43) revealed no differences between groups, further indicating an unimpaired 
liver function and carbohydrate metabolism, respectively, during XN treatment. 
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Figure 4.43 Analysis of hepatic glycogen content of xanthohumol treated (XN) and control (Ctrl.) 
mice. 
 
In addition, we analyzed CYP2E1 mRNA expression since it is known to be 
regulated on the transcriptional level in response to xenobiotics as well as under 
conditions of hepatic inflammation or metabolic and endocrine disorders 
(Gonzalez 2007; Ioannides 2008). Consistent with our other findings, hepatic 
CYP2E1 mRNA expression was not affected in XN fed mice (Figure 4.44).  
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Figure 4.44 CYP2E1 mRNA expression of xanthohumol treated (XN) and control (Ctrl.) mice 
(control arbitrarily set to 1). 
 
Furthermore, we analyzed the expression of genes known to be increased during 
liver inflammation. TNF and IL-1α are well-known markers for inflammation, the 
chemokine MCP-1 and the adhesion molecule ICAM-1 are responsible for 
infiltration of inflammatory cells into the liver, while p47phox is a subunit of 
neutrophil NADPH oxidase, which functions a generator of ROS in response to 
inflammatory stimuli. In addition, we measured hepatic collagen type I (coll-I) and 
TGF-β mRNA expression as early markers of liver fibrosis, a hallmark of chronic 
hepatic injury. None of these genes showed different mRNA expression levels in 
XN treated and control mice (Table 4.3).  
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Table 4.3: Hepatic mRNA expression levels of genes indicative for liver inflammation and fibrosis 
(mean ± stdv; control arbitrarily set to 1) 
 
Gene  control  XN p-value 
TNF 1.0 ± 0.32 1.09 ± 0.60 0.771 
IL-1α 1.0 ± 0.30 0.69 ± 0.36 0.142 
MCP-1 1.0 ± 0.85 0.95 ± 0.41 0.903 
ICAM-1 1.0 ± 0.29 1.12 ± 0.23 0.443 
p47phox 1.0 ± 0.35 1.12 ± 0.07 0.421 
coll-I 1.0 ± 0.20 0.97 ± 0.28 0.851 
TGF-β 1.0 ± 0.23 1.04 ± 0.22 0.797 
 
4.3.5 Comparison of cytotoxicity in murine and human 
hepatocytes in vitro 
In preliminary analyses we compared the effect of XN on cell viability of murine 
and human primary hepatocytes (PMH and PHH, respectively) in vitro.  
We found significantly increased LDH and AST levels in the supernatant of 
cultured PMH at concentrations as low as 50 µM XN (Figure 4.45), whereas PHH 
revealed no significant increase even at concentrations as high as 100 µM XN 
(see Figure 4.26 and see also results presented in the previous chapter 4.1.3). 
 
Ctrl. 25 50 75 100
LD
H
 
se
cr
et
io
n
[C
tr
l. 
s
et
1]
XN (µM)
Ctrl. 25 50 75 100
AS
T 
se
cr
et
io
n
[C
tr
l. 
se
t1
]
XN (µM)
0
1
2
3
*
*
*
0
1
2
3
4
5
*
*
*
LD
H
 
se
cr
et
io
n
[C
tr
l. 
s
et
1]
AS
T 
se
cr
et
io
n
[C
tr
l. 
se
t1
]
 
Figure 4.45 Primary murine hepatocytes (PMH) were incubated with xanthohumol (XN) at the 
indicated concentrations for 24 h. Viability was assessed as release of LDH and AST into the 
supernatants. *: p<0.05 compared to control. 
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4.3.6 Summary 
Here, we fed female BALB/c mice with a standard diet supplemented with 
xanthohumol for three weeks and achieved a daily dose of approximately 1000 mg 
xanthohumol /kg body weight per day. There were no significant differences in 
body weight or food intake between xanthohumol-treated and control mice (that 
received pure standard diet). Macroscopical and histopathological examination of 
liver, kidney, colon, lung, heart, spleen and thymus revealed no signs of 
xanthohumol-toxicity, and biochemical serum analysis confirmed normal organ 
function. Further, serum glucose levels and hepatic glycogen content as well as 
hepatic CYP2E1 mRNA expression levels were unaffected by xanthohumol 
treatment. Also mRNA expression of several genes indicative of early hepatic 
inflammation and fibrosis, a hallmark of chronic liver injury, did not differ between 
xanthohumol treated and control mice. In summary, these results indicate that oral 
administration of xanthohumol exhibits no adverse effects on major organ function 
and homeostasis in mice. Particularly, hepatotoxic effects of xanthohumol could be 
ruled out confirming a good safety profile of xanthohumol as basis for further 
studies in humans. 
Although in vitro data are only preliminary and in vitro data can not be fully 
transferred to the in vivo situation, the difference of murine and human 
hepatocytes regarding XN-mediated cytotoxic effects points to an at least 2-fold 
higher sensitivity of PMH compared to PHH. Thus, it may be speculated that the 
range of safe XN application with regards to hepatoxicity is even higher than 
1000 mg XN/kg body weight per day in humans. 
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5 Discussion 
 
Xanthohumol (XN) exhibits several biological effects (see chapter 2.4), however, 
with regards to effects on liver cells or liver diseases, respectively, only few data 
were available (see also chapter 2.6). The central aim of this thesis was to 
address this issue. In particular, we analyzed the effects of XN on hepatic 
inflammation and fibrosis (see chapter 4.1) as well as on hepatocellular carcinoma 
(HCC) cells (see chapter 4.2). Further, we assessed the safety profile of XN in vivo 
by feeding high doses of XN to BALB/c mice (see chapter 4.3). 
 
In the following, the discussion is divided into three main chapters apposite to the 
arrangement of the results in chapter 4: 
 
5.1 Xanthohumol and hepatic inflammation and fibrosis 
5.2 Xanthohumol and hepatocellular carcinoma 
5.3 Safety profile of xanthohumol 
 
5.1 Xanthohumol and hepatic inflammation and fibrosis 
The first aim of this thesis was to analyze the effects of XN on hepatic 
inflammation and fibrosis. After in vitro experiments with primary human liver cells 
we also assessed in vivo data using a murine NASH model. 
 
5.1.1 In vitro effects of xanthohumol on primary human liver 
cells 
Different pathophysiological mechanisms relevant for liver inflammation and 
fibrosis have been affected in HSC in vitro. Thus, HSC activation was inhibited 
while apoptosis of activated HSC was induced at XN concentrations as low as 
5 µM. In contrast and importantly, 20-fold higher XN concentrations (100 µM) did 
not induce cytotoxic effects in primary human hepatocytes (PHH) in vitro (see also 
chapter 4.2.2). Moreover, XN inhibited MCP-1 and IL-8 expression in HSC and 
PHH, respectively. Both chemokines are regulated by NFκB and increased levels 
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are associated with more severe liver inflammation and fibrosis progression in 
NASH (Haukeland et al. 2006; Jarrar et al. 2008). Further, NFκB activation is a 
central pathophysiological mechanism during HSC activation (Elsharkawy et al. 
2005; Hellerbrand et al. 1998a; Hellerbrand et al. 1998b), and importantly, XN 
inhibited basal as well as cytokine induced NFκB activity in HSC in vitro. 
 
5.1.2 In vivo effects of xanthohumol in a murine NASH model 
Based on these in vitro findings and the recently reported potential of XN to 
ameliorate metabolic disorders (Casaschi et al. 2004; Nozawa 2005; Tabata et al. 
1997; Yang et al. 2007), we decided to apply an experimental NASH model to test 
the effect of XN on hepatic fibrogenesis in vivo. However, murine NASH models 
that do lead to hepatic fibrosis are limited (Anstee and Goldin 2006). To screen the 
therapeutic efficacy of XN in vivo we applied a dietary model (Paigen-diet, see 
also chapter 2.7.5.5.5) that has been recently shown to induce the pathology of 
steatohepatitis with HSC activation and finally caused precirrhotic steatohepatitis 
(Matsuzawa et al. 2007). Additional feeding of XN reduced levels of serum 
transaminases and hepatic expression of proinflammatory genes compared to 
mice fed only with the NASH inducing Paigen-diet. Moreover, XN treatment 
significantly inhibited hepatic expression of profibrogenic genes and activation of 
HSC in vivo. Finally, it has to be noted that the liver body weight ratio, a well 
known surrogate marker for hepatic steatosis and fibrosis, was almost completely 
normalized in XN-fed mice in comparison to mice fed with the NASH inducing 
Paigen-diet. 
It is known that steatosis is mainly caused by cholesterol in this model (Matsuzawa 
et al. 2007; Vergnes et al. 2003) and that cholesterol induced oxidative stress is 
responsible for hepatic inflammation and NFκB activation (Matsuzawa et al. 2007; 
Vergnes et al. 2003; Wouters et al. 2008). In line with this, we found a significant 
increase of hepatic cholesterol levels in mice fed this diet but this increase was not 
affected by the addition of XN to the NASH diet. In a previous study hepatic 
cholesterol levels showed a lowered trend in XN-fed KK-Ay mice, a model for 
obesity and type 2 diabetes (Nozawa 2005). Further, feeding XN induced hepatic 
CYP7A1 expression (Nozawa 2005). CYP7A1 a.k.a. cholesterol-7α-hydroxylase 
catalyzes the initial step in cholesterol catabolism and bile acid synthesis. 
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However, the bile acid cholic acid, a main constituent of the Paigen-diet, strongly 
represses hepatic CYP7A1 expression (Watanabe et al. 2004), and it has been 
shown that cholic acid is necessary to induce profibrogenic gene expression in this 
model (Vergnes et al. 2003). Therefore, we speculate that the latter mechanism 
makes the effect of XN on hepatic cholesterol ineffective. However and strikingly, 
despite the fact that steatosis is not affected by XN in this model, hepatic 
inflammation, and even more importantly, HSC activation and profibrogenic gene 
expression were almost completely blunted in mice fed XN. Thus one may 
hypothesize that XN has therapeutic efficacy also in not steatosis-related liver 
injury. 
 
5.1.3 Xanthohumol as a therapeutic agent for chronic liver 
diseases 
Beer is the major dietary source of XN, but the average content of XN in beer is 
not high enough to produce a protective effect in humans. XN levels in beer are 
very low (approximately 0.1-1 mg/l) depending on the type of beer. Lager and 
pilsener beers have fairly low levels of this compound and highest levels are found 
in stout or porter (Stevens et al. 1999). Further, a brewing process has been 
developed that produces a beer that contains 10 times the amount of XN as 
traditional brews (Wunderlich et al. 2005). Still, a person would have to drink more 
than 10,000 liters of beer per day to consume the same amount of XN as applied 
in the present animal study. Regardless, there is certainly unanimous hesitancy 
among researchers to recommend drinking alcohol to avoid any kind of disease 
because of the fine line between moderate and binge drinking. Certainly, this is 
even more true in case of chronic liver disease. However, XN can be isolated from 
hops in large quantities and examined further for its use as a dietary supplement 
for prevention of NASH. Still, caution has to be taken that more research is 
needed before it is known whether the findings of the present study can be applied 
to humans. Our and other animal toxicity studies (see chapters 4.3 and 5.3) and 
our in vitro experiments using human liver cells (see chapters 4.1.3 and 4.2.2) 
provide evidence that XN may not be harmful to humans, but further safety and 
efficacy studies in vivo are required before XN can be recommended as a human 
dietary supplement for the treatment or the prevention of liver disease. However, 
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the present study indicates the potential of XN as a functional nutrition to 
ameliorate inflammation and fibrosis in chronic liver disease. 
 
5.2 Xanthohumol and hepatocellular carcinoma 
Hepatocellular cancer (HCC) develops in most cases on the basis of a fibrotic liver 
caused by chronic hepatic inflammation (see also chapter 2.7.4.1). Ameliorating 
hepatic inflammation and fibrosis per se may be beneficial for preventing 
development of HCC. However, considering the numerous reports of XN-mediated 
effects on various cancer cell types (Colgate et al. 2007; Delmulle et al. 2006; 
Goto et al. 2005; Miranda et al. 1999; Pan et al. 2005; Vanhoecke et al. 2005a), 
also direct effects of XN on HCC cells may be hypothesized, thus, indicating the 
potential to use this natural occurring chalcone for HCC prevention as well as for 
treatment of already established HCC. 
 
The second aim of this thesis was to analyze the effects of XN on viability and 
function of HCC cells. 
 
5.2.1 Effects of xanthohumol on HCC cell viability 
We observed significant cell death in HCC cells (HepG2 and Huh7) upon 
stimulation with XN at a concentration of 25 µM, and analysis of the time course of 
caspase-3/7 activation indicated that XN induced cell death is caused by apoptosis 
rather than other cytotoxic effects at this concentration, while XN concentration 
higher than 50 µM led to a rapid and almost complete detachment of HCC cells in 
vitro. XN induced cell death has been described in cell lines derived from various 
cancers at similar concentrations as observed in the present study (Colgate et al. 
2007; Lee et al. 2007; Lust et al. 2005; Miranda et al. 1999; Monteiro et al. 2007; 
Pan et al. 2005). Thus, stimulation of prostate cancer cells with 20 µM XN resulted 
in an approximately halved viability (Colgate et al. 2007), and a XN concentration 
of 100 µM induced 100% cell death in breast cancer cells (Miranda et al. 1999). 
Recently, Ho et al. reported that XN induced apoptosis in two HCC cell lines in 
vitro (Ho et al. 2008). However, in this study considerably higher XN 
concentrations (> 200 µM) were required to induce death of all HCC cells. One 
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reason for this discrepancy might be the different HCC cell lines used (HA22T and 
Hep3B in the study of Ho et al., versus HepG2 and Huh7 cells in our experiments). 
Furthermore, Ho et al. used a hop extract containing 95.7% XN for their studies. 
Thus, confounding antagonizing effects of concomitant secondary hop 
constituents can not be excluded.  
 
5.2.2 Functional effects of xanthohumol on HCC cells 
In addition to viability, we analyzed functional effects of XN on HCC cells. Previous 
reports revealed an anti-proliferative effect of XN on prostate cancer, breast 
cancer, colon cancer and leukaemia cells (Dell'Eva et al. 2007; Delmulle et al. 
2006; Pan et al. 2005; Vanhoecke et al. 2005a). However, we are the first 
reporting a growth inhibitory effect of XN on HCC cells at concentrations as low as 
15 µM. Most likely the analysis of anti-proliferative effects of XN is overlapped by 
its pro-apoptotic and cytotoxic effects. However, our dose-response studies clearly 
indicate that the significant anti-proliferative effect of XN observed already in the 
low concentration range can not be exclusively explained by these confounding 
mechanisms of XN action. 
 
Of note, we further revealed that XN inhibits the migratory potential of HCC cells in 
vitro. A higher migration potential in cancer cells is associated with an increased 
tendency for metastasis, and therefore, with higher malignancy. Also for migration 
studies we chose conditions excluding that the observed effects of XN are only 
explained by confounding mechanisms on cell viability. To the best of our 
knowledge, an effect of XN on the migratory potential of cancerous cells has not 
been described in previous reports. 
 
5.2.3 Effects on NFκB activity and IL-8 expression in HCC cells 
Furthermore, we demonstrated that XN inhibits TNF induced NFκB activity in HCC 
cells in vitro, a situation that reflects the in vivo situation since HCC almost 
exclusively develops and progresses on the basis of chronic liver inflammation 
(Pikarsky et al. 2004).  
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The transcriptional factor NFκB plays a key role in regulating immune responses 
and cell survival. Incorrect regulation of NFκB has been linked to cancer and 
inflammation. Increased NFκB activity is a common strategy of cancer cells to 
evade apoptosis, and further, has been shown to promote proliferation as well as 
migration of tumorous cells including HCC cells (Amann et al. 2009; Salvi et al. 
2009; Shen and Tergaonkar 2009; Shirouzu et al. 2008; Zhang et al. 2009). Thus, 
potential NFκB inhibitors like XN may have beneficial effects in cancer treatment 
and prevention (Shen and Tergaonkar 2009). XN is known to decrease NFκB 
activity in various cancer cell types in vitro (Albini et al. 2006; Colgate et al. 2007), 
but until now, data concerning NFκB regulating effects of XN in HCC cells were 
missing. 
In our experiments it was critical to exclude unspecific effects (e.g. paracrine 
effects caused by dying/dead cells), thus we applied XN at a very low dose 
(2.5 µM). XN exhibited no effects on basal NFκB activity, but significantly blunted 
TNF induced NFκB activity in XN treated HCC cells. 
TNF and other members of the TNF superfamily are known to be capable of 
inducing cell death via death receptor mediated apoptosis pathways in tumor cells, 
and thus, appear attractive for cancer treatment (Van Horssen et al. 2006). 
However, one of the major obstacles regarding their therapeutic application is the 
adaptive resistance due to activation of the NFκB pathway (Bertazza and Mocellin 
2008; Falschlehner et al. 2007). Therefore, suppression of NFκB appears as 
potential approach in overcoming the resistance to TNF induced apoptosis.  
 
Furthermore, NFκB regulates the expression of the pro-inflammatory chemokine 
IL-8 in HCC cells (Dong et al. 2001; Joshi-Barve et al. 2007), and previous studies 
have shown that IL-8 promotes the progression of HCC (Kubo et al. 2005; Ren et 
al. 2003). Here, we could detect a significant attenuation of TNF induced increase 
of IL-8 mRNA expression by treatment with XN, which may be beneficial in HCC 
treatment. 
 
Together, these data indicate the potential of XN as a therapeutic agent for HCC 
treatment. Moreover, the shown pro-apoptotic, anti-proliferative, anti-migrational 
and anti-inflammatory effects of XN in HCC cells may work together synergistically 
with other reported effects of XN, e.g. the reactive oxygen species (ROS) 
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scavenging properties of XN (Gerhäuser et al. 2002). ROS related signals may 
play important roles in the development of HCC (Tien and Savaraj 2006). In 
addition, ROS mediated induction of resistance gene expression, a major problem 
in cancer treatment, has been discussed (Tien and Savaraj 2006). ROS 
scavenging by XN could suppress these processes. Moreover, Lee et al. could 
demonstrate that XN clearly decreases the mRNA levels of the drug efflux genes 
ABCB1 (MDR1), ABCC1 (MRP1), ABCC2 (MRP2), and ABCC3 (MRP3) in lung 
cancer cells, which are known to be responsible for drug resistances (Lee et al. 
2007). Hence, aside from the direct anti-cancerous effect of XN, a conjunction of 
XN with other anticancer chemotherapeutic agents could be a promising strategy 
to reduce drug resistances in cancer treatment.  
Furthermore, inhibitory effects of XN on protein expression of the inducible nitric 
oxide synthase (iNOS), and suppression of cyclooxygenase (COX) activity were 
reported (Gerhäuser et al. 2002; Zhao et al. 2003). Both iNOS and COX are linked 
to inflammation as well as to carcinogenesis and angiogenesis. Interestingly, a 
study by Calvisi et al. indicates that the crosstalk between inducible nitric oxide 
synthase (iNOS) and NFκB cascades promotes HCC progression (Calvisi et al. 
2008), and Amann et al. could demonstrate that suppression of iNOS signaling in 
HCC cells attenuates pro-migrational effects of factors derived from activated 
hepatic stellate cells (Amann et al. 2009).  
 
5.2.4 Effects of xanthohumol on non-malignant cells 
Very few studies have addressed the important question whether XN exhibits 
(unwanted) effects on healthy tissue or non-tumorous cells, respectively. Yang et 
al. described loss of viability in approximately 90% of 3T3-L1 cells, a murine 
adipocyte cell line, after 24 h treatment with 75 µM XN (Yang et al. 2007). In the 
(non-malignant) murine hepatoma cell line AML12 the maximal applied 
concentration of 225 µM XN (24 h) induced toxicity in approximately 50% of cells 
as reported by Ho et al. (Ho et al. 2008). However, to the best of our knowledge, 
no data have been reported concerning the effect of XN on primary human cells. 
In the present study we analyzed the effect of XN on the viability of primary human 
hepatocytes (PHH). Noteworthy, we found that viability of PHH was not affected 
after 24 h stimulation with a XN concentration as high as 100 µM.  
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5.2.5 Xanthohumol as therapeutic agent for HCC treatment 
These data further promote the use of XN as anti-cancer therapeutic, and first 
insights regarding bioavailability and metabolism of flavonoids and polyphenols 
suggest that particularly HCC appears as predestined cancer for oral XN 
treatment. Metabolism of flavonoids is rather complex and depends on the 
structure, the dose and the matrix, but there is evidence that several congeners 
reach (to a certain extend) the small intestine unchanged (Spencer 2003), where 
absorption into the mesenteric circulation takes place. Accordingly, it can be 
presumed that upon oral administration of XN hepatocytes as well as HCC cells 
are exposed to intact XN reaching the liver via portal circulation after absorption. In 
general, metabolism of most xenobiotics takes place mainly in hepatocytes, and it 
has been already shown that XN is effectively metabolized by rat and human liver 
microsomes in vitro (Nikolic et al. 2005; Yilmazer et al. 2001a; Yilmazer et al. 
2001b). These studies suggest that XN is probably completely metabolized in the 
liver, and therefore, it may be predicted that circulating plasma concentrations 
won’t reach potentially effective levels for most other cancers if XN is administered 
orally. 
 
In vivo studies in mice and rats (Hussong et al. 2005; Vanhoecke et al. 2005b) as 
well as our in vitro experiments using human hepatocytes indicate a very good 
safety profile of XN. Still, further safety and efficacy studies are required to 
evaluate the suitability of XN as a therapeutic agent for HCC (see next chapter).  
 
However, the demonstrated pro-apoptotic, anti-proliferative, anti-migratory and 
anti-inflammatory effects of XN on HCC cells in vitro may act synergistically also in 
vivo, and herewith, XN appears as attractive and promising therapeutic agent for 
this highly aggressive tumor. 
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5.3 Safety profile of xanthohumol 
There is a rising interest in the beneficial effects of natural compounds on various 
complaints and diseases. Especially the large group of polyphenols has received 
much attention. However, potential side effects of these compounds have to be 
identified before considering them as potential therapeutic agents. 
 
The third aim of this thesis was to assess a safety profile of orally applied 
xanthohumol in vivo. For this purpose we fed BALB/c mice with high doses of 
xanthohumol for 3 weeks. 
 
5.3.1 Previously performed safety studies 
Xanthohumol (XN), the principle prenylflavonoid found in hops, has been shown to 
possess a variety of beneficial effects (Gerhäuser 2005a; Gerhäuser 2005b; 
Gerhäuser et al. 2002; Stevens and Page 2004; Zanoli and Zavatti 2008) (see also 
chapter 2.4), and previous studies revealed a maximal tolerable dose of more than 
1000 mg XN/kg b.w. in rats. Two safety studies of chronic oral XN application in 
mice and rats, respectively, confirmed the absence of toxicity or remarkable 
treatment-related changes with one exception: In the study of Hussong et al. 
feeding of 1000 mg XN/kg b.w. per day for 4 weeks led to a reduction of total liver 
weight and a reduced hepatic glycogen content as assessed by histological 
investigation. The authors interpreted these findings as suggestive of mild 
hepatoxicity (Hussong et al. 2005). In contrast, the other safety study by 
Vanhoecke et al. did not reveal any signs of hepatoxicity but has been performed 
in mice and with a lower dose (approximately 35 mg/kg b.w. per day) (Vanhoecke 
et al. 2005b). Thus, in the present study we fed mice for three weeks with a XN 
enriched diet to achieve a daily XN dose of approximately 1000 mg/kg b.w., and 
studied possible side effects with a focus on the affection of liver function and 
homeostasis.  
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5.3.2 Effects of xanthohumol on inner organs 
Macroscopical, histological and serum analysis revealed no toxic effects or 
abnormalities in inner organs including lung, heart, thymus, spleen, kidney and 
colon in XN treated animals. These findings are in line with all previous in vivo 
studies, but this report is the first that analyzed chronic application of such a high 
dose of XN in mice. Lipase activity as a marker for potential toxicity in the exocrine 
pancreas did not differ between XN fed mice and controls. Blood urea nitrogen 
and creatinine concentrations suggested an intact kidney function. Together with 
the unaltered albumin serum levels this data indicate an unchanged glomerular 
filtration rate. Normal sodium and potassium as well as total protein serum levels, 
respectively, further confirmed normal organ function after XN treatment.  
 
Little is known about bioavailability and metabolism of XN in vivo. In general, the 
extent of dietary polyphenol absorption in the small intestine is rather limited 
(10-20%) (Kuhnle et al. 2000; Spencer et al. 1999), thereby implying that a large 
proportion reaches the colon. Here, we didn’t find any signs of XN induced toxicity 
on the colon. Microscopic sections revealed normal colonic tissue structure, 
excrements appeared normal except for the yellowish color caused by excreted 
XN and colon length, a gross marker for colitis, did not differ between XN treated 
and control mice. Additionally, low serum endotoxin levels in both groups indicate 
an intact barrier function of the gut. 
 
5.3.3 Effects of xanthohumol on liver function 
Another organ which has to confront relatively high concentrations of orally applied 
XN is the liver. The part of ingested XN, which is absorbed in the small intestine, is 
pooled in the portal vein blood, which then reaches the liver unfiltered and 
undiluted. As already mentioned in chapter 5.2.5, it has been shown that XN is 
effectively metabolized by rat and human liver microsomes in vitro (Nikolic et al. 
2005; Yilmazer et al. 2001a; Yilmazer et al. 2001b). Therefore, XN is probably 
completely metabolized in the liver and plasma concentrations presumably won’t 
reach high levels, which is a well-known phenomenon for many other polyphenolic 
compounds (Scalbert and Williamson 2000). However, an accumulation of XN in 
hepatocytes could be speculated. For silibinin, a polyphenolic compound from the 
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milk thistle, known for its hepatoprotective effects, Singh et al. could show that 
after 5 weeks of feeding the highest concentration of silibinin were detected in the 
liver (Singh et al. 2002), thus confirming the rationality of the long-established 
application in this particular organ (Comelli et al. 2007).  
Possible accumulation of XN in the liver, a high hepatic metabolism rate resulting 
in possibly active metabolites and potential therapeutic approaches to treat liver 
diseases with XN show the importance of identifying any adverse side effects of 
XN on the liver. 
 
In the present study neither macroscopic, morphometric, histological nor 
biochemical analysis revealed any signs of hepatoxicity in XN treated mice. 
Albumin and glucose levels remained unaffected by XN feeding, and transaminase 
serum levels (ALT and AST) were not elevated. Further, mRNA expression levels 
of several genes known to be involved in early hepatic inflammation or 
fibrogenesis were not affected by XN application. TNF (tumor necrosis factor) and 
IL-1α (interleukin-1 alpha) are well-known markers for inflammation, the NFκB 
regulated proteins MCP-1 (monocyte chemoattractant protein-1) and ICAM-1 
(inter-cellular adhesion molecule-1) are responsible for infiltration of inflammatory 
cells into the liver and p47phox is a subunit of neutrophil NADPH oxidase, which 
functions as a generator of ROS in response to inflammatory stimuli (oxidative 
burst). No changes in mRNA expression levels of any of these genes could be 
detected after XN treatment. Also coll-1 (collagen type 1) and TGF-β (transforming 
growth factor beta) mRNA expression levels, sensitive markers for beginning 
fibrogenesis, did not differ between XN treated and control mice. Keeping in mind 
that mRNA expression is a sensitive marker for even slight hepatic affection, 
hepatic injury appears very unlikely even after longer periods of XN intake.  
 
Moreover, quantitative assessment of hepatic glycogen content as well as hepatic 
CYP2E1 mRNA expression revealed no difference between XN treated and 
control mice. CYP2E1 expression is known to be regulated on the transcriptional 
level in response to various xenobiotics, but also to inflammatory diseases and 
metabolic and nutritional disorders like diabetes, obesity and non alcoholic 
steatohepatitis (Cederbaum et al. 2009; Gonzalez 2007; Ioannides 2008; Raucy et 
al. 1991; Weltman et al. 1998; Woodcroft et al. 2002; Yun et al. 1992). 
Discussion  111 
Furthermore, it is enhanced by starvation or low carbohydrate diets causing an 
increased rate of gluconeogenesis at the expense of emerging reactive oxygen 
species (ROS) (Hong et al. 1987; Jaeschke et al. 2002; Johansson et al. 1990; 
Lieber 1999; Lieber 2004; Lindros and Jarvelainen 1998; Teschke et al. 1981; Yoo 
et al. 1991).  
 
These findings as well as the unaffected liver body weight ratios are in contrast to 
the previous study by Hussong et al. in rats (Hussong et al. 2005). Certainly, 
species differences may account in part for these discrepancies as shown for 
several other metabolic liver functions (Bun et al. 2005; Petersen et al. 1994). 
Further, histological analysis of glycogen content, as performed in the study of 
Hussong et al., is only a rough measurement, and both liver weight and hepatic 
glycogen content are only unspecific and vague indicators of hepatic injury. For 
example, also unspecific stress or fasting affects hepatic glycogen levels within 
hours (Aoki et al. 2009; Curi et al. 1990; Suh et al. 2007). Moreover, XN is a ligand 
of the farnesoid X receptor (FXR) and affects several genes involved in 
carbohydrate metabolism (Nozawa 2005) (see also chapter 2.4.7). Therefore and 
although not observed in the present study, reduced hepatic glycogen levels in 
response to XN treatment may be completely explained by direct effects of XN on 
carbohydrate metabolism rather than a potential hepatotoxic effect. 
 
In conclusion, our study confirms the safety of oral XN administration to mice in a 
dose as high as 1000 mg/kg b.w per day. Especially, potential hepatotoxicity could 
be ruled out. Moreover, preliminary in vitro experiments with primary murine 
hepatocytes (PMH) (see chapter 4.3.5) point to an at least 3-fold higher sensitivity 
of PMH in comparison to primary human hepatocytes (PHH). Thus, although in 
vitro data can not be fully transferred to the in vivo situation, it may be speculated 
that range of safe XN application with regards to hepatoxicity is even higher than 
1000 mg XN/kg b.w. in humans. However, the safety profile of XN surely has to be 
further studied in humans, but taken together our data indicate the safe use of XN 
as a therapeutic agent or functional nutrient. 
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5.4 Conclusion 
As mentioned in the introduction XN exerts a variety of possibly beneficial effects. 
The reported anti-inflammatory, antioxidant and anti-infective effects of XN give 
rise to the presumption that this naturally occurring chalcone may also be useful 
for prevention or treatment of liver diseases, where chronic inflammation, oxidative 
stress and (mainly viral) infection play critical roles in most cases.  
 
Additionally, the reported effects of XN on carbohydrate and lipid metabolism may 
be beneficial for patients with metabolic disorders like type 2 diabetes mellitus 
and/or insulin resistance. One of the major sites of carbohydrate and lipid 
metabolism and homeostasis is the liver, again identifying this specific organ as an 
interesting study object regarding XN-mediated effects.  
 
Viral infections, chronic alcohol abuse and the metabolic syndrome are major risk 
factors for chronic liver disease. They lead to chronic hepatic inflammation, and if 
hepatitis continues, there is progression to liver fibrosis and subsequently to 
cirrhosis. The latter is the main risk factor for the development of hepatocellular 
cancer (HCC). Thus, regarding the known biological effects of XN liver disease 
appeared as attractive target for therapeutic XN application.  
 
Considering bioavailability and metabolism of XN, the liver seems to be a 
predestined organ for XN-treatment, because the liver may be one of the few 
organs where oral application of this polyphenolic compound lead to 
therapeutically useful concentrations. In general, nutritional compounds have a 
higher concentration in the portal vein which directly connects the gut with the 
liver; distribution in the systemic circulation logically leads to a drop of the 
concentration. Additionally, a main function of the liver is to metabolize 
xenobiotics. Hepatocytes are specialized in confronting and taking up 
unmetabolized xenobiotics in high concentrations, and subsequently metabolize 
them. In many cases, the blood concentrations of xenobiotics or drugs are greatly 
reduced during the first liver passage, i.e. before the xenobiotic/drug reaches the 
systemic circulation (“first-pass effect”). 
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Taken together, the liver seems to be a promising target for XN treatment. 
However, up until now only very few studies have addressed this interesting point.  
Therefore, the major aim of this thesis was to evaluate the potential of XN as a 
therapeutic agent for liver diseases.  
 
First, we analyzed the effects of XN on hepatic stellate cells (HSC), the central 
mediators of liver fibrogenesis and could detect significant induction of apoptosis 
in vitro. Furthermore, XN inhibits NFκB activation and expression of NFκB 
dependent proinflammatory chemokines in HCS. These data suggest that XN may 
suppress inflammation and fibrogenesis in injured livers. In vivo, feeding of XN 
reduced levels of serum transaminases and hepatic expression of proinflammatory 
genes in a murine model of non-alcoholic steatohepatitis (NASH), showing XN’s 
hepatoprotective effect. Further, also in vivo XN treatment significantly inhibited 
hepatic expression of profibrogenic genes and activation of HSC.  
 
Inhibition of inflammation and fibrosis may be beneficial in treatment of various 
liver diseases like non-alcoholic fatty liver diseases, alcohol induced liver diseases 
or chronic viral hepatitis. But also for prevention of HCC anti-inflammatory and 
anti-fibrotic agents may be useful. This aggressive cancer mostly develops and 
progresses, respectively, on the basis of a fibrotic liver caused by chronic hepatic 
inflammation.  
Considering the numerous reports of anti-cancerous (and anti-angiogenic) effects 
of XN, evaluation of XN effects on HCC cells seemed to be promising. Indeed, XN 
showed significant cytotoxic and pro-apoptotic effects on HCC cells in doses 
where non-malignant primary human hepatocytes (PHH) were completely 
unaffected. Moreover, we could show for the first time that XN repressed HCC cell 
proliferation and migration in vitro as well as TNF induced NFκB activity and 
interleukin-8 expression in HCC cells at even lower concentrations. These data 
indicate, that XN may be used both for prevention and treatment of HCC. Surely, 
to evaluate these therapy options further studies are required. 
 
However, potential adverse side effects of XN have to be identified before its 
therapeutic application. Especially the detection of even slight hepatotoxic effects, 
a frequent problem of novel therapeutics, is crucial. This is even more relevant if 
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intending to treat patients with impaired liver function or liver injury. Here, we 
detected no signs of XN-mediated toxicity after feeding XN in a dose of 
approximately 1000 mg XN/kg b.w. per day to female BALB/c mice for 3 weeks. 
Macroscopical and histopathological examination of liver, kidney, colon, lung, 
heart, spleen and thymus revealed no signs of XN-toxicity, and biochemical serum 
analysis confirmed normal organ function. Further, serum glucose levels and 
hepatic glycogen content as well as hepatic CYP2E1 mRNA expression levels 
were unaffected by xanthohumol treatment. Also mRNA expression of several 
genes indicative of early hepatic inflammation and fibrosis, a hallmark of chronic 
liver injury, did not differ between xanthohumol treated and control mice.  
 
In conclusion, xanthohumol has the potential to ameliorate NASH induced liver 
injury as well as different pro-tumorigenic mechanisms known to promote HCC 
progression. Together with the good safety profile these data suggest the potential 
use of xanthohumol as functional nutrient or therapeutic agent to prevent or treat 
liver diseases like NASH or HCC. 
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7 Abbreviations 
α-sma alpha-smooth muscle actin 
a.k.a. also known as 
a.M. am Main 
ALT alanine aminotransferase 
approx. approximately 
APS ammonium persulfate 
arb. arbituary 
AST aspartate aminotransferase 
ATP adenosine triphosphate 
b.w. body weight 
BCA bicinchonic acid 
BMI body mass index 
bp base pairs 
BSA bovine serum albumin 
°C degree Celsius 
ca. circa 
cDNA complementary DNA 
coll-I collagen type I 
Ctrl. Control 
d day 
Da dalton (= 1.66018 x 10-24 g) 
DAPI 4',6-diamidino-2-phenylindole 
DMX desmethylxanthohumol 
dest. destilled 
DMEM Dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
e.g.  exempli gratia 
ECM extracellular matrix 
EDTA ethylene diamine tetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
ELISA enzyme linked immunosorbent assay 
et al. et alii 
EU ELISA unit 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
g gram 
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gluc. glucose 
h hour 
H2Odest. destilled water 
HCC hepatocellular carcinoma 
HCl hydrochloric acid 
HRP horse radish peroxidase 
HSC hepatic stellate cells 
Hz hertz 
i.e. id est 
i.v. intravenous 
IC50 half-maximal inhibitory concentrations 
ICAM-1 inter-cellular adhesion molecule-1 
IκBα inhibitory kappa B alpha 
IKK IκB kinase 
IL-1α interleukin-1 alpha 
IL-8 interleukin-8 
IX isoxanthohumol 
kDa kilodalton 
l liter 
LDH lactate dehydrogenase 
LPS lipopolysaccharide 
M molar, mol/l 
mA miliampere 
MCP-1 monocyte chemoattractant protein-1 = CCL2 
mg miligram 
Mg magnesium 
µl microliter 
µm micrometer 
ml mililiter 
MIC minimal inhibitory concentration 
min minute 
mM milimolar 
mm millimeter 
mmol millimol 
MMP matrix metalloproteinase 
mRNA messenger RNA 
NAD+ nicotinamide adenine dinucleotide (oxidized form) 
NADH nicotinamide adenine dinucleotide (reduced form) 
NaOH sodium hydroxide 
neg. negative 
NFκB nuclear factor kappa B 
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OD optical density 
p-value probability value (statistics) 
PL palmitic acid 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
pH pondus hydrogenii 
6-PN 6-prenylxanthohumol 
8-PN 8-prenylxanthohumol 
PHH primary human hepatocytes 
PI propidium iodide 
PMH primary murine hepatocytes 
qRT-PCR quantitative realtime-PCR 
RNA ribonucleic acid 
RNase ribonuclease 
ROS reactive oxygen species 
rRNA ribosomal RNA 
RT room temperature 
s second 
SDS sodium dodecyl sulfate 
TC50 half-maximal toxic concentrations 
TE Tris EDTA 
TEMED N,N,N',N'-tetramethylethylenediamine 
TG triglyceride 
TGF-β transforming growth factor-beta 
TI therapeutic index 
TIMP-1 tissue inhibitor of metalloproteinases-1 
TNF tumor necrosis factor 
Tris tris(hydroxymethyl)aminomethane 
TWEEN Polyoxyethylene sorbitan monolaurate 
U unit 
UV ultraviolet 
V volt 
v/v volume per volume 
Vol. volume 
vs. versus 
w week 
w/v weight per volumen 
w/w weight per weight 
XN xanthohumol 
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